<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561195</url>
  </required_header>
  <id_info>
    <org_study_id>B5091009</org_study_id>
    <nct_id>NCT02561195</nct_id>
  </id_info>
  <brief_title>A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years</brief_title>
  <official_title>A Phase 2, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Safety, Tolerability, And Immunogenicity Of Two 3-dose Regimens Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 To 85 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate a Clostridium difficile vaccine in healthy adults aged 65-85
      years. Each subject will initially receive 3 doses of vaccine on 1 of 2 vaccination
      schedules. The study will assess the safety and tolerability of the vaccine as well as the
      subjects' immune response to the vaccine. One year after the third dose subjects that did not
      receive placebo will be randomized to receive a fourth dose. Subjects will be followed for up
      to 4 years after their third vaccination.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 16, 2015</start_date>
  <completion_date type="Anticipated">March 23, 2020</completion_date>
  <primary_completion_date type="Actual">March 7, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 37</measure>
    <time_frame>Day 37 (7 days after Vaccination 3 of Day 1, 8 and 30 regimen)</time_frame>
    <description>Toxin A antibodies were measured using neutralization assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Month 7</measure>
    <time_frame>Month 7 (1 month after Vaccination 3 of Month 0, 1 and 6 regimen)</time_frame>
    <description>Toxin A antibodies were measured using neutralization assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Day 37</measure>
    <time_frame>Day 37 (7 days after Vaccination 3 of Day 1, 8 and 30 regimen)</time_frame>
    <description>Toxin B antibodies were measured using neutralization assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Month 7</measure>
    <time_frame>Month 7 (1 month after Vaccination 3 of Month 0, 1 and 6 regimen)</time_frame>
    <description>Toxin B antibodies were measured using neutralization assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Day 37</measure>
    <time_frame>Day 37 (7 days after Vaccination 3 of Day 1, 8 and 30 regimen)</time_frame>
    <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Month 7</measure>
    <time_frame>Month 7 (1 month after Vaccination 3 of Month 0, 1 and 6 regimen)</time_frame>
    <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants With Local Reactions by Severity Within 7 Days After Vaccination 1</measure>
    <time_frame>within 7 days After Vaccination 1</time_frame>
    <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (grade 1) (did not interfere with activity), moderate (grade 2)(interfered with activity), severe (grade 3) (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 centimeter [cm]), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 1</measure>
    <time_frame>within 14 days After Vaccination 1</time_frame>
    <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 2</measure>
    <time_frame>within 14 days After Vaccination 2</time_frame>
    <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 2</measure>
    <time_frame>within 14 days after Vaccination 2</time_frame>
    <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 3</measure>
    <time_frame>within 14 days after Vaccination 3</time_frame>
    <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 3</measure>
    <time_frame>within 14 days after Vaccination 3</time_frame>
    <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants With Systemic Events by Severity Within 7 Days After Vaccination 1</measure>
    <time_frame>within 7 days after Vaccination 1</time_frame>
    <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 degree Celsius (C)), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 1</measure>
    <time_frame>within 14 days after Vaccination 1</time_frame>
    <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 2</measure>
    <time_frame>within 14 days after Vaccination 2</time_frame>
    <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 2</measure>
    <time_frame>within 14 days after Vaccination 2</time_frame>
    <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 3</measure>
    <time_frame>within 14 days after Vaccination 3</time_frame>
    <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 3</measure>
    <time_frame>within 14 days after Vaccination 3</time_frame>
    <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants With Treatment Emergent Adverse Events (AEs)</measure>
    <time_frame>From Vaccination 1 up to 28 days after Vaccination 3 (Day 58)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants With Treatment Emergent Adverse Events (AEs)</measure>
    <time_frame>From Vaccination 1 up to 28 days after Vaccination 3 (Day 208)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants With Treatment Emergent Serious Adverse Events (SAEs)</measure>
    <time_frame>From Vaccination 1 up to 6 months after Vaccination 3 (Month 7)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. Treatment-emergent serious adverse events are events between first dose of study drug and up to 6 months after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants With Treatment Emergent Serious Adverse Events (SAEs)</measure>
    <time_frame>From Vaccination 1 up to 6 months after Vaccination 3 (Month 12)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. Treatment-emergent serious adverse events are events between first dose of study drug and up to 6 months after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 1, 8, 15, 30, and Month 2, 4, 7, 13</measure>
    <time_frame>Day 1, 8, 15, 30 and Month 2, 4, 7, 13</time_frame>
    <description>Toxin A antibodies were measured using neutralization assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Day 1, 8, 15, 30 and Month 2, 4, 7, 13</measure>
    <time_frame>Day 1, 8, 15, 30 and Month 2, 4, 7, 13</time_frame>
    <description>Toxin B antibodies were measured using neutralization assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Day 1, 8, 15, 30 and Month 2, 4, 7, 13</measure>
    <time_frame>Day 1, 8, 15, 30 and Month 2, 4, 7, 13</time_frame>
    <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 1, 30, 37, 187 and Month 2, 6, 12, 18</measure>
    <time_frame>Day 1, 30, 37, 187 and Month 2, 6, 12, 18</time_frame>
    <description>Toxin A antibodies were measured using neutralization assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for for Toxin B at Day 1, 30, 37, 187 and Month 2, 6, 12, 18</measure>
    <time_frame>Day 1, 30, 37, 187 and Month 2, 6, 12, 18</time_frame>
    <description>Toxin B antibodies were measured using neutralization assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Day 1, 30, 37, 187 and Month 2, 6, 12, 18</measure>
    <time_frame>Day 1, 30, 37, 187 and Month 2, 6, 12, 18</time_frame>
    <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Geometric Mean Concentration of Toxin A Specific Neutralizing Antibody Levels at Day 1, 8, 15, 30, 37 and Month 2, 4, 7, 13</measure>
    <time_frame>Day 1, 8, 15, 30, 37 and Month 2, 4, 7, 13</time_frame>
    <description>Geometric mean concentration (GMC) of toxin A specific antibody levels was calculated using back transformations of the logarithmically transformed means of assay results. Confidence interval (CI) for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Geometric Mean Concentration of Toxin B Specific Neutralizing Antibody Levels at Day 1, 8, 15, 30, 37 and Month 2, 4, 7, 13</measure>
    <time_frame>Day 1, 8, 15, 30, 37 and Month 2, 4, 7, 13</time_frame>
    <description>GMC of toxin B specific antibody levels was calculated using back transformations of the logarithmically transformed means of assay results. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Geometric Mean Concentration of Toxin A Specific Neutralizing Antibody Levels at Day 1, 30, 37, 187 and Month 2, 6, 7, 12, 18</measure>
    <time_frame>Day 1, 30, 37, 187 and Month 2, 6, 7, 12, 18</time_frame>
    <description>GMC of toxin A specific antibody levels was calculated using back transformations of the logarithmically transformed means of assay results. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Geometric Mean Concentration of Toxin B Specific Neutralizing Antibody Levels at Day 1, 30, 37, 187 and Month 2, 6, 7, 12, 18</measure>
    <time_frame>Day 1, 30, 37, 187 and Month 2, 6, 7, 12, 18</time_frame>
    <description>GMC of toxin B specific antibody levels was calculated using back transformations of the logarithmically transformed means of assay results. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Geometric Mean Fold Rise in Toxin A Specific Neutralizing Antibody Levels From Baseline at Day 8, 15, 30, 37 and Month 2, 4, 7, 13</measure>
    <time_frame>Day 8, 15, 30, 37 and Month 2, 4, 7, 13</time_frame>
    <description>Geometric mean fold rise (GMFR) in toxin A specific antibody levels was calculated using back transformations of the logarithmically transformed means of fold rise from baseline with assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Geometric Mean Fold Rise in Toxin B Specific Neutralizing Antibody Levels From Baseline at Day 8, 15, 30, 37 and Month 2, 4, 7, 13</measure>
    <time_frame>Day 8, 15, 30, 37 and Month 2, 4, 7, 13</time_frame>
    <description>GMFR in toxin B specific antibody levels was calculated using back transformations of the logarithmically transformed means of fold rise from baseline with assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Geometric Mean Fold Rise in Toxin A Specific Neutralizing Antibody Levels From Baseline at Day 30, 37, 187 and Month 2, 6, 7, 12, 18</measure>
    <time_frame>Day 30, 37, 187 and Month 2, 6, 7, 12, 18</time_frame>
    <description>GMFR in toxin A specific antibody levels was calculated using back transformations of the logarithmically transformed means of fold rise from baseline with assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Geometric Mean Fold Rise in Toxin B Specific Neutralizing Antibody Levels From Baseline at Day 30, 37, 187 and Month 2, 6, 7, 12, 18</measure>
    <time_frame>Day 30, 37, 187 and Month 2, 6, 7, 12, 18</time_frame>
    <description>GMFR for toxin B specific antibody levels was calculated using back transformations of the logarithmically transformed means of fold rise from baseline with assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin A Specific Antibody Levels at Day 8, 15, 30, 37 and Month 2, 4, 7, 13</measure>
    <time_frame>Day 8, 15, 30, 37 and Month 2, 4, 7, 13</time_frame>
    <description>Toxin A antibodies were measured using neutralization assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin B Specific Antibody Levels at Day 8, 15, 30, 37 and Month 2, 4, 7, 13</measure>
    <time_frame>Day 8, 15, 30, 37 and Month 2, 4, 7, 13</time_frame>
    <description>Toxin B antibodies were measured using neutralization assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving&gt;=4,&gt;=8,&gt;=16,&gt;=32 Fold Rise From Baseline in Both Toxin A and Toxin B Specific Antibody Levels at Day 8, 15, 30, 37 and Month 2, 4, 7, 13</measure>
    <time_frame>Day 8, 15, 30, 37 and Month 2, 4, 7, 13</time_frame>
    <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin A Specific Antibody Levels at Day 30, 37, 187 and Month 2, 6, 7, 12, 18</measure>
    <time_frame>Day 30, 37, 187 and Month 2, 6, 7, 12, 18</time_frame>
    <description>Toxin A antibodies were measured using neutralization assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin B Specific Antibody Levels at Day 30, 37, 187 and Month 2, 6, 7, 12, 18</measure>
    <time_frame>Day 30, 37, 187 and Month 2, 6, 7, 12, 18</time_frame>
    <description>Toxin A antibodies were measured using neutralization assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving&gt;=4,&gt;=8,&gt;=16,&gt;=32 Fold Rise From Baseline in Both Toxin A and Toxin B Antibody Levels at Day 30, 37, 187 and Month 2, 6, 7, 12, 18</measure>
    <time_frame>Day 30, 37, 187 and Month 2, 6, 7, 12, 18</time_frame>
    <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</measure>
    <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</measure>
    <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</measure>
    <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration for Toxin A Specific Neutralizing Antibody Levels at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</measure>
    <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration for Toxin B Specific Neutralizing Antibody Levels at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</measure>
    <time_frame>day 8, 30; month 6, 12, 18, 24, 30, 36 after Vaccination 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise in Toxin A Specific Neutralizing Antibody Levels From Baseline at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</measure>
    <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise in Toxin B Specific Neutralizing Antibody Levels From Baseline at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</measure>
    <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin A Specific Antibody Levels at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</measure>
    <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin B Specific Antibody Levels at Day 8, 30, Month 6, 12, 18, 24, 30 and 36</measure>
    <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving&gt;=4,&gt;=8,&gt;=16,&gt;=32 Fold Rise From Baseline in Both Toxin A and Toxin B Antibody Levels at Day 8, 30, Month 6, 12, 18, 24, 30 and 36</measure>
    <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Local Reactions by Severity Within 14 Days of Vaccination 4</measure>
    <time_frame>within 14 days of Vaccination 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Systemic Events by Severity Within 14 Days of Vaccination 4</measure>
    <time_frame>within 14 days of Vaccination 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment Emergent Adverse Events (AEs)</measure>
    <time_frame>From Vaccination 4 up to 28 days after Vaccination 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment Emergent Serious Adverse Events (SAEs)</measure>
    <time_frame>From Vaccination 4 up to 6 months after Vaccination 4</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">855</enrollment>
  <condition>Clostridium Difficile Associated Disease</condition>
  <arm_group>
    <arm_group_label>Low-dose C. difficile Vaccine (accelerated schedule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose C. difficile Vaccine (accelerated schedule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (accelerated schedule)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose C. difficile Vaccine (non-accelerated schedule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose C. difficile Vaccine (non-accelerated schedule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (non-accelerated schedule)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Clostridium difficile Vaccine</intervention_name>
    <description>0.5 mL intramuscular injection.</description>
    <arm_group_label>Low-dose C. difficile Vaccine (accelerated schedule)</arm_group_label>
    <arm_group_label>High-dose C. difficile Vaccine (accelerated schedule)</arm_group_label>
    <arm_group_label>Low-dose C. difficile Vaccine (non-accelerated schedule)</arm_group_label>
    <arm_group_label>High-Dose C. difficile Vaccine (non-accelerated schedule)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5 mL intramuscular injection</description>
    <arm_group_label>Placebo (accelerated schedule)</arm_group_label>
    <arm_group_label>Placebo (non-accelerated schedule)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects

          -  Aged 65 to 85 years

        Additional Inclusion Criteria for the extension Stage:

          -  Receipt of all 3 doses of C difficile vaccine (100 µg or 200 µg antigen dose level) in
             the original portion of the study.

        Exclusion Criteria:

          -  Proven or suspected prior episode of Clostridium difficile associated diarrhea

          -  Unstable chronic medical condition

          -  Disease requiring significant change in therapy or hospitalization for worsening
             disease within 8 weeks before receipt of study vaccine

          -  Serious chronic disorders

          -  Congenital or acquired immunodeficiency disorders

          -  Rheumatologic disorders or other illnesses requiring chronic treatment with known
             immunosuppressant medications.

          -  Active or treated leukemia or lymphoma or bone marrow disorder

          -  Any contraindication to vaccination or vaccine components including previous
             anaphylactic reaction to any vaccine or vaccine-related components

        Additional Exclusion Criteria for the Extension Stage:

          -  Subjects originally randomized to placebo during the original portion of the study.

          -  Subjects who have already completed Visit 9 prior to study unblinding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QPS-MRA, LLC (Broward Research Group)</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QPS-MRA, LLC (Miami Research Associates)</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East-West Medical Research Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince &amp; Associates Clinical Research, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince &amp; Associates Clinical Research, Inc</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Center For Drug Development, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5091009&amp;StudyName=A%20Phase%202%2C%20Placebo-controlled%2C%20Randomized%2C%20Observer-blinded%20Study%20To%20Evaluate%20The%20Safety%2C%20Tolerability%2C%20And%20Immunogenicity%20Of%20Two%203-dose%20Regimens%20Of%20A%20Clostridium%20Difficile%20Vaccine%20In%20Healthy%20Adults%20Aged%2065%20To%2085%20Years</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2015</study_first_posted>
  <results_first_submitted>March 5, 2018</results_first_submitted>
  <results_first_submitted_qc>March 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2018</results_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridium difficile, Vaccine.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
          <description>Participants received 100 microgram (mcg) of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
        </group>
        <group group_id="P2">
          <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
          <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
        </group>
        <group group_id="P3">
          <title>Placebo: Day 1, 8 and 30 Regimen</title>
          <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
        </group>
        <group group_id="P4">
          <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
          <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
        </group>
        <group group_id="P5">
          <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
          <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
        </group>
        <group group_id="P6">
          <title>Placebo: Month 0, 1 and 6 Regimen</title>
          <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="184"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="183"/>
                <participants group_id="P5" count="183"/>
                <participants group_id="P6" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="184"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="183"/>
                <participants group_id="P5" count="183"/>
                <participants group_id="P6" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="157"/>
                <participants group_id="P5" count="155"/>
                <participants group_id="P6" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer meets eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer willing to participate</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who received at least 1 dose of the investigational product and had safety data available.</population>
      <group_list>
        <group group_id="B1">
          <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
          <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
        </group>
        <group group_id="B2">
          <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
          <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
        </group>
        <group group_id="B3">
          <title>Placebo: Day 1, 8 and 30 Regimen</title>
          <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
        </group>
        <group group_id="B4">
          <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
          <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
        </group>
        <group group_id="B5">
          <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
          <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
        </group>
        <group group_id="B6">
          <title>Placebo: Month 0, 1 and 6 Regimen</title>
          <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="182"/>
            <count group_id="B2" value="184"/>
            <count group_id="B3" value="61"/>
            <count group_id="B4" value="183"/>
            <count group_id="B5" value="183"/>
            <count group_id="B6" value="61"/>
            <count group_id="B7" value="854"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="183"/>
                    <measurement group_id="B5" value="183"/>
                    <measurement group_id="B6" value="61"/>
                    <measurement group_id="B7" value="854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="97"/>
                    <measurement group_id="B6" value="37"/>
                    <measurement group_id="B7" value="461"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="90"/>
                    <measurement group_id="B5" value="86"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Race: White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="151"/>
                    <measurement group_id="B5" value="157"/>
                    <measurement group_id="B6" value="56"/>
                    <measurement group_id="B7" value="763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ethnicity: Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="168"/>
                    <measurement group_id="B5" value="172"/>
                    <measurement group_id="B6" value="57"/>
                    <measurement group_id="B7" value="715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity: Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 37</title>
        <description>Toxin A antibodies were measured using neutralization assay.</description>
        <time_frame>Day 37 (7 days after Vaccination 3 of Day 1, 8 and 30 regimen)</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 37</title>
          <description>Toxin A antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="5.2" upper_limit="24.1"/>
                    <measurement group_id="O2" value="68.4" lower_limit="60.9" upper_limit="75.3"/>
                    <measurement group_id="O3" value="85.5" lower_limit="79.1" upper_limit="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Month 7</title>
        <description>Toxin A antibodies were measured using neutralization assay.</description>
        <time_frame>Month 7 (1 month after Vaccination 3 of Month 0, 1 and 6 regimen)</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Month 7</title>
          <description>Toxin A antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="98.2" lower_limit="94.7" upper_limit="99.6"/>
                    <measurement group_id="O3" value="95.6" lower_limit="91.1" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Day 37</title>
        <description>Toxin B antibodies were measured using neutralization assay.</description>
        <time_frame>Day 37 (7 days after Vaccination 3 of Day 1, 8 and 30 regimen)</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Day 37</title>
          <description>Toxin B antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.0" upper_limit="9.6"/>
                    <measurement group_id="O2" value="29.8" lower_limit="23.1" upper_limit="37.3"/>
                    <measurement group_id="O3" value="38.8" lower_limit="31.3" upper_limit="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Month 7</title>
        <description>Toxin B antibodies were measured using neutralization assay.</description>
        <time_frame>Month 7 (1 month after Vaccination 3 of Month 0, 1 and 6 regimen)</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Month 7</title>
          <description>Toxin B antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="2.1" upper_limit="18.2"/>
                    <measurement group_id="O2" value="74.8" lower_limit="67.5" upper_limit="81.3"/>
                    <measurement group_id="O3" value="87.3" lower_limit="81.1" upper_limit="92.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Day 37</title>
        <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
        <time_frame>Day 37 (7 days after Vaccination 3 of Day 1, 8 and 30 regimen)</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Day 37</title>
          <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="26.3" lower_limit="19.9" upper_limit="33.6"/>
                    <measurement group_id="O3" value="38.8" lower_limit="31.3" upper_limit="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Month 7</title>
        <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
        <time_frame>Month 7 (1 month after Vaccination 3 of Month 0, 1 and 6 regimen)</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Month 7</title>
          <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="74.2" lower_limit="66.8" upper_limit="80.8"/>
                    <measurement group_id="O3" value="86.1" lower_limit="79.7" upper_limit="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants With Local Reactions by Severity Within 7 Days After Vaccination 1</title>
        <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (grade 1) (did not interfere with activity), moderate (grade 2)(interfered with activity), severe (grade 3) (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 centimeter [cm]), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
        <time_frame>within 7 days After Vaccination 1</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N (overall number of participants analyzed) signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants With Local Reactions by Severity Within 7 Days After Vaccination 1</title>
          <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (grade 1) (did not interfere with activity), moderate (grade 2)(interfered with activity), severe (grade 3) (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 centimeter [cm]), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N (overall number of participants analyzed) signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="1.8" upper_limit="15.9"/>
                    <measurement group_id="O2" value="19.0" lower_limit="13.5" upper_limit="25.5"/>
                    <measurement group_id="O3" value="15.8" lower_limit="10.9" upper_limit="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="1.8" upper_limit="15.9"/>
                    <measurement group_id="O2" value="17.9" lower_limit="12.6" upper_limit="24.3"/>
                    <measurement group_id="O3" value="14.2" lower_limit="9.5" upper_limit="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.3" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.1" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.1" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.3" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.1" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 1</title>
        <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
        <time_frame>within 14 days After Vaccination 1</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 1</title>
          <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="182"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="2.7" upper_limit="18.1"/>
                    <measurement group_id="O2" value="24.2" lower_limit="18.1" upper_limit="31.1"/>
                    <measurement group_id="O3" value="19.8" lower_limit="14.3" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="1.8" upper_limit="15.9"/>
                    <measurement group_id="O2" value="22.0" lower_limit="16.2" upper_limit="28.7"/>
                    <measurement group_id="O3" value="19.2" lower_limit="13.8" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                    <measurement group_id="O2" value="2.2" lower_limit="0.6" upper_limit="5.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="3.9"/>
                    <measurement group_id="O3" value="2.2" lower_limit="0.6" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.1" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="3.9"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.1" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 2</title>
        <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
        <time_frame>within 14 days After Vaccination 2</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 2</title>
          <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="31.7" lower_limit="24.9" upper_limit="39.0"/>
                    <measurement group_id="O3" value="41.3" lower_limit="34.0" upper_limit="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="25.6" lower_limit="19.4" upper_limit="32.6"/>
                    <measurement group_id="O3" value="36.3" lower_limit="29.3" upper_limit="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="6.1" lower_limit="3.1" upper_limit="10.7"/>
                    <measurement group_id="O3" value="4.5" lower_limit="1.9" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="9.2"/>
                    <measurement group_id="O2" value="4.4" lower_limit="1.9" upper_limit="8.6"/>
                    <measurement group_id="O3" value="6.7" lower_limit="3.5" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="9.2"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                    <measurement group_id="O3" value="2.8" lower_limit="0.9" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.3" upper_limit="4.8"/>
                    <measurement group_id="O3" value="1.7" lower_limit="0.3" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.3" upper_limit="4.8"/>
                    <measurement group_id="O3" value="2.2" lower_limit="0.6" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="3.3" lower_limit="1.2" upper_limit="7.1"/>
                    <measurement group_id="O3" value="5.6" lower_limit="2.7" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                    <measurement group_id="O3" value="3.9" lower_limit="1.6" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.3" upper_limit="4.8"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 2</title>
        <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
        <time_frame>within 14 days after Vaccination 2</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 2</title>
          <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="1.1" upper_limit="14.1"/>
                    <measurement group_id="O2" value="27.8" lower_limit="21.4" upper_limit="35.1"/>
                    <measurement group_id="O3" value="27.7" lower_limit="21.2" upper_limit="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="1.1" upper_limit="14.1"/>
                    <measurement group_id="O2" value="23.3" lower_limit="17.3" upper_limit="30.2"/>
                    <measurement group_id="O3" value="25.4" lower_limit="19.2" upper_limit="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="4.5" lower_limit="2.0" upper_limit="8.8"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="3.4" lower_limit="1.3" upper_limit="7.3"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.4" upper_limit="4.9"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="4.0" lower_limit="1.6" upper_limit="8.0"/>
                    <measurement group_id="O3" value="4.0" lower_limit="1.6" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.6" upper_limit="5.7"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="1.7" lower_limit="0.4" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 3</title>
        <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
        <time_frame>within 14 days after Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 3</title>
          <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0.4" upper_limit="12.1"/>
                    <measurement group_id="O2" value="22.9" lower_limit="16.9" upper_limit="29.8"/>
                    <measurement group_id="O3" value="22.2" lower_limit="16.2" upper_limit="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0.4" upper_limit="12.1"/>
                    <measurement group_id="O2" value="18.9" lower_limit="13.4" upper_limit="25.5"/>
                    <measurement group_id="O3" value="21.1" lower_limit="15.2" upper_limit="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="4.0" lower_limit="1.6" upper_limit="8.1"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.1" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.6" upper_limit="5.7"/>
                    <measurement group_id="O3" value="5.3" lower_limit="2.4" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="4.1"/>
                    <measurement group_id="O3" value="1.8" lower_limit="0.4" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="4.1"/>
                    <measurement group_id="O3" value="3.5" lower_limit="1.3" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.9" upper_limit="6.5"/>
                    <measurement group_id="O3" value="5.3" lower_limit="2.4" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.6" upper_limit="5.7"/>
                    <measurement group_id="O3" value="2.9" lower_limit="1.0" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.6" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 3</title>
        <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
        <time_frame>within 14 days after Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants With Local Reactions by Severity Within 14 Days After Vaccination 3</title>
          <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.5-5.0 cm), moderate (&gt;5.0 to 10.0 cm), severe (&gt;10.0 cm) and grade 4 (necrosis).</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O2" value="22.0" lower_limit="16.0" upper_limit="29.1"/>
                    <measurement group_id="O3" value="26.1" lower_limit="19.5" upper_limit="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="19.6" lower_limit="13.9" upper_limit="26.5"/>
                    <measurement group_id="O3" value="21.7" lower_limit="15.6" upper_limit="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.4" upper_limit="5.1"/>
                    <measurement group_id="O3" value="4.3" lower_limit="1.8" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="4.2" lower_limit="1.7" upper_limit="8.4"/>
                    <measurement group_id="O3" value="4.3" lower_limit="1.8" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1.3" upper_limit="7.6"/>
                    <measurement group_id="O3" value="3.7" lower_limit="1.4" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0.7" upper_limit="6.0"/>
                    <measurement group_id="O3" value="5.0" lower_limit="2.2" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0.7" upper_limit="6.0"/>
                    <measurement group_id="O3" value="4.3" lower_limit="1.8" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants With Systemic Events by Severity Within 7 Days After Vaccination 1</title>
        <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 degree Celsius (C)), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
        <time_frame>within 7 days after Vaccination 1</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants With Systemic Events by Severity Within 7 Days After Vaccination 1</title>
          <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 degree Celsius (C)), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="178"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="178"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="178"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="178"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="178"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Grade 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" lower_limit="5.8" upper_limit="24.2"/>
                    <measurement group_id="O2" value="7.8" lower_limit="4.3" upper_limit="12.8"/>
                    <measurement group_id="O3" value="9.3" lower_limit="5.5" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="4.7" upper_limit="22.2"/>
                    <measurement group_id="O2" value="7.3" lower_limit="3.9" upper_limit="12.1"/>
                    <measurement group_id="O3" value="7.7" lower_limit="4.2" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.3" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Grade 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="4.7" upper_limit="22.2"/>
                    <measurement group_id="O2" value="7.3" lower_limit="3.9" upper_limit="12.1"/>
                    <measurement group_id="O3" value="11.5" lower_limit="7.2" upper_limit="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="2.7" upper_limit="18.1"/>
                    <measurement group_id="O2" value="5.6" lower_limit="2.7" upper_limit="10.0"/>
                    <measurement group_id="O3" value="7.7" lower_limit="4.2" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.4" upper_limit="11.3"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.3" upper_limit="4.8"/>
                    <measurement group_id="O3" value="3.8" lower_limit="1.6" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="7.0" upper_limit="26.2"/>
                    <measurement group_id="O2" value="10.6" lower_limit="6.5" upper_limit="16.1"/>
                    <measurement group_id="O3" value="18.6" lower_limit="13.2" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="4.7" upper_limit="22.2"/>
                    <measurement group_id="O2" value="7.8" lower_limit="4.3" upper_limit="12.8"/>
                    <measurement group_id="O3" value="9.3" lower_limit="5.5" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.4" upper_limit="11.3"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.9" upper_limit="6.4"/>
                    <measurement group_id="O3" value="8.7" lower_limit="5.1" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Grade 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.4" upper_limit="11.3"/>
                    <measurement group_id="O2" value="6.7" lower_limit="3.5" upper_limit="11.4"/>
                    <measurement group_id="O3" value="8.7" lower_limit="5.1" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                    <measurement group_id="O2" value="5.0" lower_limit="2.3" upper_limit="9.3"/>
                    <measurement group_id="O3" value="4.4" lower_limit="1.9" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.3" upper_limit="4.8"/>
                    <measurement group_id="O3" value="4.4" lower_limit="1.9" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Grade 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.9" upper_limit="6.4"/>
                    <measurement group_id="O3" value="8.7" lower_limit="5.1" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                    <measurement group_id="O3" value="3.8" lower_limit="1.6" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.3" upper_limit="4.8"/>
                    <measurement group_id="O3" value="4.4" lower_limit="1.9" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Grade 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 1</title>
        <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
        <time_frame>within 14 days after Vaccination 1</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 1</title>
          <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="182"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0.3" upper_limit="4.7"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" lower_limit="11.9" upper_limit="33.7"/>
                    <measurement group_id="O2" value="19.8" lower_limit="14.3" upper_limit="26.3"/>
                    <measurement group_id="O3" value="19.2" lower_limit="13.8" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="7.0" upper_limit="26.2"/>
                    <measurement group_id="O2" value="17.0" lower_limit="11.9" upper_limit="23.3"/>
                    <measurement group_id="O3" value="13.7" lower_limit="9.1" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="1.0" upper_limit="13.7"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.9" upper_limit="6.3"/>
                    <measurement group_id="O3" value="4.4" lower_limit="1.9" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.1" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" lower_limit="17.1" upper_limit="40.8"/>
                    <measurement group_id="O2" value="15.9" lower_limit="10.9" upper_limit="22.1"/>
                    <measurement group_id="O3" value="16.5" lower_limit="11.4" upper_limit="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" lower_limit="10.6" upper_limit="31.8"/>
                    <measurement group_id="O2" value="10.4" lower_limit="6.4" upper_limit="15.8"/>
                    <measurement group_id="O3" value="9.3" lower_limit="5.5" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="2.7" upper_limit="18.1"/>
                    <measurement group_id="O2" value="5.5" lower_limit="2.7" upper_limit="9.9"/>
                    <measurement group_id="O3" value="6.6" lower_limit="3.5" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" lower_limit="19.9" upper_limit="44.3"/>
                    <measurement group_id="O2" value="28.6" lower_limit="22.1" upper_limit="35.7"/>
                    <measurement group_id="O3" value="26.9" lower_limit="20.6" upper_limit="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="7.0" upper_limit="26.2"/>
                    <measurement group_id="O2" value="14.8" lower_limit="10.0" upper_limit="20.8"/>
                    <measurement group_id="O3" value="12.6" lower_limit="8.2" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" lower_limit="5.8" upper_limit="24.2"/>
                    <measurement group_id="O2" value="13.2" lower_limit="8.6" upper_limit="19.0"/>
                    <measurement group_id="O3" value="13.2" lower_limit="8.6" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.4" upper_limit="11.3"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.1" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="3.7" upper_limit="20.2"/>
                    <measurement group_id="O2" value="14.3" lower_limit="9.5" upper_limit="20.2"/>
                    <measurement group_id="O3" value="14.8" lower_limit="10.0" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.4" upper_limit="11.3"/>
                    <measurement group_id="O2" value="8.2" lower_limit="4.7" upper_limit="13.2"/>
                    <measurement group_id="O3" value="6.0" lower_limit="3.1" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="1.8" upper_limit="15.9"/>
                    <measurement group_id="O2" value="5.5" lower_limit="2.7" upper_limit="9.9"/>
                    <measurement group_id="O3" value="7.7" lower_limit="4.3" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.1" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="3.7" upper_limit="20.2"/>
                    <measurement group_id="O2" value="9.9" lower_limit="6.0" upper_limit="15.2"/>
                    <measurement group_id="O3" value="16.5" lower_limit="11.4" upper_limit="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.4" upper_limit="11.3"/>
                    <measurement group_id="O2" value="5.5" lower_limit="2.7" upper_limit="9.9"/>
                    <measurement group_id="O3" value="8.2" lower_limit="4.7" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="1.0" upper_limit="13.7"/>
                    <measurement group_id="O2" value="4.4" lower_limit="1.9" upper_limit="8.5"/>
                    <measurement group_id="O3" value="7.7" lower_limit="4.3" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 2</title>
        <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
        <time_frame>within 14 days after Vaccination 2</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 2</title>
          <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0.4" upper_limit="11.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.7" lower_limit="0.3" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0.4" upper_limit="11.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.7" lower_limit="0.3" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="3.9" upper_limit="21.2"/>
                    <measurement group_id="O2" value="9.4" lower_limit="5.6" upper_limit="14.7"/>
                    <measurement group_id="O3" value="12.3" lower_limit="7.9" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="1.9" upper_limit="16.7"/>
                    <measurement group_id="O2" value="6.7" lower_limit="3.5" upper_limit="11.4"/>
                    <measurement group_id="O3" value="8.9" lower_limit="5.2" upper_limit="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0.4" upper_limit="11.9"/>
                    <measurement group_id="O2" value="2.2" lower_limit="0.6" upper_limit="5.6"/>
                    <measurement group_id="O3" value="3.4" lower_limit="1.2" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="7.3" upper_limit="27.4"/>
                    <measurement group_id="O2" value="12.2" lower_limit="7.8" upper_limit="17.9"/>
                    <measurement group_id="O3" value="13.4" lower_limit="8.8" upper_limit="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="1.9" upper_limit="16.7"/>
                    <measurement group_id="O2" value="8.3" lower_limit="4.7" upper_limit="13.4"/>
                    <measurement group_id="O3" value="7.8" lower_limit="4.3" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="2.9" upper_limit="19.0"/>
                    <measurement group_id="O2" value="3.9" lower_limit="1.6" upper_limit="7.8"/>
                    <measurement group_id="O3" value="5.6" lower_limit="2.7" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" lower_limit="11.2" upper_limit="33.4"/>
                    <measurement group_id="O2" value="17.8" lower_limit="12.5" upper_limit="24.2"/>
                    <measurement group_id="O3" value="19.0" lower_limit="13.5" upper_limit="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="1.9" upper_limit="16.7"/>
                    <measurement group_id="O2" value="10.0" lower_limit="6.0" upper_limit="15.3"/>
                    <measurement group_id="O3" value="10.6" lower_limit="6.5" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="3.9" upper_limit="21.2"/>
                    <measurement group_id="O2" value="7.8" lower_limit="4.3" upper_limit="12.7"/>
                    <measurement group_id="O3" value="7.8" lower_limit="4.3" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0.4" upper_limit="11.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="2.9" upper_limit="19.0"/>
                    <measurement group_id="O2" value="10.6" lower_limit="6.5" upper_limit="16.0"/>
                    <measurement group_id="O3" value="13.4" lower_limit="8.8" upper_limit="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0.4" upper_limit="11.9"/>
                    <measurement group_id="O2" value="5.0" lower_limit="2.3" upper_limit="9.3"/>
                    <measurement group_id="O3" value="8.9" lower_limit="5.2" upper_limit="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="1.1" upper_limit="14.4"/>
                    <measurement group_id="O2" value="5.0" lower_limit="2.3" upper_limit="9.3"/>
                    <measurement group_id="O3" value="3.9" lower_limit="1.6" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="1.1" upper_limit="14.4"/>
                    <measurement group_id="O2" value="6.1" lower_limit="3.1" upper_limit="10.7"/>
                    <measurement group_id="O3" value="7.8" lower_limit="4.3" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="9.2"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.3" upper_limit="4.8"/>
                    <measurement group_id="O3" value="6.7" lower_limit="3.5" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0.4" upper_limit="11.9"/>
                    <measurement group_id="O2" value="4.4" lower_limit="1.9" upper_limit="8.6"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 2</title>
        <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
        <time_frame>within 14 days after Vaccination 2</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 2</title>
          <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.4" upper_limit="4.9"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.4" upper_limit="4.9"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="9.7" upper_limit="30.9"/>
                    <measurement group_id="O2" value="20.5" lower_limit="14.8" upper_limit="27.2"/>
                    <measurement group_id="O3" value="14.1" lower_limit="9.4" upper_limit="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="3.8" upper_limit="20.8"/>
                    <measurement group_id="O2" value="15.3" lower_limit="10.4" upper_limit="21.5"/>
                    <measurement group_id="O3" value="10.2" lower_limit="6.1" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="2.8" upper_limit="18.7"/>
                    <measurement group_id="O2" value="4.5" lower_limit="2.0" upper_limit="8.8"/>
                    <measurement group_id="O3" value="3.4" lower_limit="1.3" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" lower_limit="11.0" upper_limit="32.8"/>
                    <measurement group_id="O2" value="14.8" lower_limit="9.9" upper_limit="20.9"/>
                    <measurement group_id="O3" value="15.3" lower_limit="10.3" upper_limit="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="3.8" upper_limit="20.8"/>
                    <measurement group_id="O2" value="9.1" lower_limit="5.3" upper_limit="14.3"/>
                    <measurement group_id="O3" value="9.6" lower_limit="5.7" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="3.8" upper_limit="20.8"/>
                    <measurement group_id="O2" value="5.1" lower_limit="2.4" upper_limit="9.5"/>
                    <measurement group_id="O3" value="5.6" lower_limit="2.7" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="9.7" upper_limit="30.9"/>
                    <measurement group_id="O2" value="23.9" lower_limit="17.8" upper_limit="30.9"/>
                    <measurement group_id="O3" value="18.1" lower_limit="12.7" upper_limit="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="2.8" upper_limit="18.7"/>
                    <measurement group_id="O2" value="11.9" lower_limit="7.5" upper_limit="17.7"/>
                    <measurement group_id="O3" value="6.2" lower_limit="3.1" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="3.8" upper_limit="20.8"/>
                    <measurement group_id="O2" value="11.4" lower_limit="7.1" upper_limit="17.0"/>
                    <measurement group_id="O3" value="11.3" lower_limit="7.0" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="2.8" upper_limit="18.7"/>
                    <measurement group_id="O2" value="11.9" lower_limit="7.5" upper_limit="17.7"/>
                    <measurement group_id="O3" value="10.2" lower_limit="6.1" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="1.1" upper_limit="14.1"/>
                    <measurement group_id="O2" value="6.3" lower_limit="3.2" upper_limit="10.9"/>
                    <measurement group_id="O3" value="5.1" lower_limit="2.4" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0.4" upper_limit="11.7"/>
                    <measurement group_id="O2" value="5.1" lower_limit="2.4" upper_limit="9.5"/>
                    <measurement group_id="O3" value="4.5" lower_limit="2.0" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="1.1" upper_limit="14.1"/>
                    <measurement group_id="O2" value="8.5" lower_limit="4.8" upper_limit="13.7"/>
                    <measurement group_id="O3" value="10.2" lower_limit="6.1" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="6.3" lower_limit="3.2" upper_limit="10.9"/>
                    <measurement group_id="O3" value="5.1" lower_limit="2.4" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0.4" upper_limit="11.7"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.6" upper_limit="5.7"/>
                    <measurement group_id="O3" value="5.1" lower_limit="2.4" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 3</title>
        <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
        <time_frame>within 14 days after Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 3</title>
          <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="1.8" lower_limit="0.4" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.1" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.0" upper_limit="9.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.1" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.0" upper_limit="9.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.1" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="6.3" upper_limit="25.8"/>
                    <measurement group_id="O2" value="3.4" lower_limit="1.3" upper_limit="7.3"/>
                    <measurement group_id="O3" value="8.2" lower_limit="4.5" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="2.9" upper_limit="19.3"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.9" upper_limit="6.5"/>
                    <measurement group_id="O3" value="7.0" lower_limit="3.7" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0.4" upper_limit="12.1"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.1" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.0" upper_limit="9.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="4.0" upper_limit="21.5"/>
                    <measurement group_id="O2" value="8.0" lower_limit="4.4" upper_limit="13.1"/>
                    <measurement group_id="O3" value="11.7" lower_limit="7.3" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="2.9" upper_limit="19.3"/>
                    <measurement group_id="O2" value="4.6" lower_limit="2.0" upper_limit="8.8"/>
                    <measurement group_id="O3" value="4.1" lower_limit="1.7" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.0" upper_limit="9.4"/>
                    <measurement group_id="O2" value="3.4" lower_limit="1.3" upper_limit="7.3"/>
                    <measurement group_id="O3" value="7.0" lower_limit="3.7" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="8.7" upper_limit="29.9"/>
                    <measurement group_id="O2" value="9.7" lower_limit="5.8" upper_limit="15.1"/>
                    <measurement group_id="O3" value="12.3" lower_limit="7.8" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="4.0" upper_limit="21.5"/>
                    <measurement group_id="O2" value="4.0" lower_limit="1.6" upper_limit="8.1"/>
                    <measurement group_id="O3" value="5.8" lower_limit="2.8" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="1.9" upper_limit="17.0"/>
                    <measurement group_id="O2" value="5.7" lower_limit="2.8" upper_limit="10.3"/>
                    <measurement group_id="O3" value="5.8" lower_limit="2.8" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0.4" upper_limit="12.1"/>
                    <measurement group_id="O2" value="5.1" lower_limit="2.4" upper_limit="9.5"/>
                    <measurement group_id="O3" value="8.2" lower_limit="4.5" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0.4" upper_limit="12.1"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.4" upper_limit="4.9"/>
                    <measurement group_id="O3" value="4.7" lower_limit="2.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="3.4" lower_limit="1.3" upper_limit="7.3"/>
                    <measurement group_id="O3" value="3.5" lower_limit="1.3" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="1.1" upper_limit="14.6"/>
                    <measurement group_id="O2" value="4.0" lower_limit="1.6" upper_limit="8.1"/>
                    <measurement group_id="O3" value="5.8" lower_limit="2.8" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.0" upper_limit="9.4"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.1" upper_limit="4.1"/>
                    <measurement group_id="O3" value="4.7" lower_limit="2.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0.4" upper_limit="12.1"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.9" upper_limit="6.5"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.1" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 3</title>
        <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
        <time_frame>within 14 days after Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants With Systemic Events by Severity Within 14 Days After Vaccination 3</title>
          <description>Systemic events included fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain and were recorded by using an e-diary. Fever was graded as mild (38.0 to 38.4 C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C), grade 4 (&gt;40.0 degree C). Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours), severe (required intravenous hydration) and grade 4 (hospitalization for hypotensive shock). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours), severe (&gt;=6 stools in 24 hours) and grade 4 (hospitalization). Headache, fatigue, new or worsening muscle pain and new or worsening joint pain was graded as mild (no interference with activity), moderate (some interference with activity), severe (prevents daily activity) and grade 4 (hospitalization).</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.1" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.1" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.2" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.2" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="4.2" upper_limit="22.6"/>
                    <measurement group_id="O2" value="16.7" lower_limit="11.4" upper_limit="23.2"/>
                    <measurement group_id="O3" value="12.4" lower_limit="7.8" upper_limit="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O2" value="11.3" lower_limit="6.9" upper_limit="17.1"/>
                    <measurement group_id="O3" value="9.3" lower_limit="5.3" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O2" value="4.8" lower_limit="2.1" upper_limit="9.2"/>
                    <measurement group_id="O3" value="3.1" lower_limit="1.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="9.3" upper_limit="31.4"/>
                    <measurement group_id="O2" value="12.5" lower_limit="7.9" upper_limit="18.5"/>
                    <measurement group_id="O3" value="14.3" lower_limit="9.3" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="5.4" upper_limit="24.9"/>
                    <measurement group_id="O2" value="8.3" lower_limit="4.6" upper_limit="13.6"/>
                    <measurement group_id="O3" value="7.5" lower_limit="3.9" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="6.8"/>
                    <measurement group_id="O3" value="6.8" lower_limit="3.5" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.1" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="6.6" upper_limit="27.1"/>
                    <measurement group_id="O2" value="20.8" lower_limit="15.0" upper_limit="27.8"/>
                    <measurement group_id="O3" value="16.8" lower_limit="11.4" upper_limit="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O2" value="14.9" lower_limit="9.9" upper_limit="21.2"/>
                    <measurement group_id="O3" value="9.3" lower_limit="5.3" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="4.2" upper_limit="22.6"/>
                    <measurement group_id="O2" value="4.8" lower_limit="2.1" upper_limit="9.2"/>
                    <measurement group_id="O3" value="6.8" lower_limit="3.5" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.1" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="4.2" upper_limit="22.6"/>
                    <measurement group_id="O2" value="8.3" lower_limit="4.6" upper_limit="13.6"/>
                    <measurement group_id="O3" value="10.6" lower_limit="6.3" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O2" value="4.2" lower_limit="1.7" upper_limit="8.4"/>
                    <measurement group_id="O3" value="5.0" lower_limit="2.2" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="3.1" upper_limit="20.3"/>
                    <measurement group_id="O2" value="4.2" lower_limit="1.7" upper_limit="8.4"/>
                    <measurement group_id="O3" value="5.6" lower_limit="2.6" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening muscle pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="4.2" upper_limit="22.6"/>
                    <measurement group_id="O2" value="7.1" lower_limit="3.7" upper_limit="12.1"/>
                    <measurement group_id="O3" value="8.1" lower_limit="4.4" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.4" upper_limit="5.1"/>
                    <measurement group_id="O3" value="5.0" lower_limit="2.2" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O2" value="4.8" lower_limit="2.1" upper_limit="9.2"/>
                    <measurement group_id="O3" value="3.1" lower_limit="1.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or worsening joint pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants With Treatment Emergent Adverse Events (AEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state.</description>
        <time_frame>From Vaccination 1 up to 28 days after Vaccination 3 (Day 58)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants With Treatment Emergent Adverse Events (AEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="182"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="23.6"/>
                    <measurement group_id="O3" value="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants With Treatment Emergent Adverse Events (AEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state.</description>
        <time_frame>From Vaccination 1 up to 28 days after Vaccination 3 (Day 208)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants With Treatment Emergent Adverse Events (AEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1"/>
                    <measurement group_id="O2" value="53.6"/>
                    <measurement group_id="O3" value="55.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants With Treatment Emergent Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. Treatment-emergent serious adverse events are events between first dose of study drug and up to 6 months after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state.</description>
        <time_frame>From Vaccination 1 up to 6 months after Vaccination 3 (Month 7)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants With Treatment Emergent Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. Treatment-emergent serious adverse events are events between first dose of study drug and up to 6 months after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="182"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="6.0"/>
                    <measurement group_id="O3" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants With Treatment Emergent Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. Treatment-emergent serious adverse events are events between first dose of study drug and up to 6 months after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state.</description>
        <time_frame>From Vaccination 1 up to 6 months after Vaccination 3 (Month 12)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants With Treatment Emergent Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. Treatment-emergent serious adverse events are events between first dose of study drug and up to 6 months after last dose of study drug that were absent before treatment or that worsened relative to pretreatment state.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="10.4"/>
                    <measurement group_id="O3" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 1, 8, 15, 30, and Month 2, 4, 7, 13</title>
        <description>Toxin A antibodies were measured using neutralization assay.</description>
        <time_frame>Day 1, 8, 15, 30 and Month 2, 4, 7, 13</time_frame>
        <population>Evaluable immunogenicity population: All eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 1, 8, 15, 30, and Month 2, 4, 7, 13</title>
          <description>Toxin A antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: All eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.1" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="4.7" lower_limit="2.0" upper_limit="9.0"/>
                    <measurement group_id="O3" value="6.7" lower_limit="3.4" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="17.0" lower_limit="11.7" upper_limit="23.4"/>
                    <measurement group_id="O3" value="25.0" lower_limit="18.6" upper_limit="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="26.3" lower_limit="19.9" upper_limit="33.6"/>
                    <measurement group_id="O3" value="36.6" lower_limit="29.2" upper_limit="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="0.4" upper_limit="12.3"/>
                    <measurement group_id="O2" value="61.4" lower_limit="53.7" upper_limit="68.7"/>
                    <measurement group_id="O3" value="85.5" lower_limit="79.1" upper_limit="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.0" upper_limit="9.7"/>
                    <measurement group_id="O2" value="29.4" lower_limit="22.7" upper_limit="36.9"/>
                    <measurement group_id="O3" value="52.4" lower_limit="44.5" upper_limit="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="15.1" lower_limit="10.0" upper_limit="21.4"/>
                    <measurement group_id="O3" value="31.4" lower_limit="24.3" upper_limit="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O2" value="10.1" lower_limit="5.9" upper_limit="15.9"/>
                    <measurement group_id="O3" value="25.8" lower_limit="19.1" upper_limit="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Day 1, 8, 15, 30 and Month 2, 4, 7, 13</title>
        <description>Toxin B antibodies were measured using neutralization assay.</description>
        <time_frame>Day 1, 8, 15, 30 and Month 2, 4, 7, 13</time_frame>
        <population>Evaluable immunogenicity population: All eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations. N= number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Day 1, 8, 15, 30 and Month 2, 4, 7, 13</title>
          <description>Toxin B antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: All eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations. N= number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="1.1" upper_limit="14.9"/>
                    <measurement group_id="O2" value="4.7" lower_limit="2.0" upper_limit="9.0"/>
                    <measurement group_id="O3" value="3.7" lower_limit="1.4" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="0.4" upper_limit="12.3"/>
                    <measurement group_id="O2" value="9.9" lower_limit="5.9" upper_limit="15.4"/>
                    <measurement group_id="O3" value="11.5" lower_limit="7.1" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="0.4" upper_limit="12.3"/>
                    <measurement group_id="O2" value="30.4" lower_limit="23.6" upper_limit="37.9"/>
                    <measurement group_id="O3" value="37.2" lower_limit="29.8" upper_limit="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="0.4" upper_limit="12.3"/>
                    <measurement group_id="O2" value="29.8" lower_limit="23.1" upper_limit="37.3"/>
                    <measurement group_id="O3" value="37.2" lower_limit="29.8" upper_limit="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.0" upper_limit="9.6"/>
                    <measurement group_id="O2" value="29.2" lower_limit="22.5" upper_limit="36.7"/>
                    <measurement group_id="O3" value="37.0" lower_limit="29.6" upper_limit="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="26.5" lower_limit="20.0" upper_limit="33.8"/>
                    <measurement group_id="O3" value="31.1" lower_limit="24.1" upper_limit="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="24.1" lower_limit="17.8" upper_limit="31.3"/>
                    <measurement group_id="O3" value="26.4" lower_limit="19.7" upper_limit="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O2" value="19.6" lower_limit="13.7" upper_limit="26.7"/>
                    <measurement group_id="O3" value="31.0" lower_limit="23.8" upper_limit="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Day 1, 8, 15, 30 and Month 2, 4, 7, 13</title>
        <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
        <time_frame>Day 1, 8, 15, 30 and Month 2, 4, 7, 13</time_frame>
        <population>Evaluable immunogenicity population: All eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations. N= number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Day 1, 8, 15, 30 and Month 2, 4, 7, 13</title>
          <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: All eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations. N= number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.3" upper_limit="7.5"/>
                    <measurement group_id="O3" value="4.8" lower_limit="2.1" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="11.7" lower_limit="7.3" upper_limit="17.5"/>
                    <measurement group_id="O3" value="18.3" lower_limit="12.7" upper_limit="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="15.8" lower_limit="10.7" upper_limit="22.1"/>
                    <measurement group_id="O3" value="20.7" lower_limit="14.8" upper_limit="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="24.0" lower_limit="17.8" upper_limit="31.1"/>
                    <measurement group_id="O3" value="36.4" lower_limit="29.0" upper_limit="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="13.5" lower_limit="8.8" upper_limit="19.6"/>
                    <measurement group_id="O3" value="24.4" lower_limit="18.0" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="8.4" lower_limit="4.7" upper_limit="13.7"/>
                    <measurement group_id="O3" value="15.7" lower_limit="10.4" upper_limit="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="6.3" lower_limit="3.1" upper_limit="11.3"/>
                    <measurement group_id="O3" value="15.5" lower_limit="10.2" upper_limit="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 1, 30, 37, 187 and Month 2, 6, 12, 18</title>
        <description>Toxin A antibodies were measured using neutralization assay.</description>
        <time_frame>Day 1, 30, 37, 187 and Month 2, 6, 12, 18</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 1, 30, 37, 187 and Month 2, 6, 12, 18</title>
          <description>Toxin A antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.2" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="17.3" lower_limit="11.8" upper_limit="24.0"/>
                    <measurement group_id="O3" value="19.1" lower_limit="13.3" upper_limit="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="43.6" lower_limit="35.8" upper_limit="51.5"/>
                    <measurement group_id="O3" value="56.7" lower_limit="48.6" upper_limit="64.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="41.1" lower_limit="33.5" upper_limit="49.1"/>
                    <measurement group_id="O3" value="57.0" lower_limit="48.9" upper_limit="64.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="15.3" lower_limit="10.2" upper_limit="21.8"/>
                    <measurement group_id="O3" value="20.3" lower_limit="14.3" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="80.2" lower_limit="73.3" upper_limit="86.1"/>
                    <measurement group_id="O3" value="84.8" lower_limit="78.2" upper_limit="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                    <measurement group_id="O2" value="71.9" lower_limit="64.2" upper_limit="78.7"/>
                    <measurement group_id="O3" value="77.4" lower_limit="70.0" upper_limit="83.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="0.5" upper_limit="13.5"/>
                    <measurement group_id="O2" value="48.7" lower_limit="40.6" upper_limit="56.9"/>
                    <measurement group_id="O3" value="53.3" lower_limit="45.0" upper_limit="61.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for for Toxin B at Day 1, 30, 37, 187 and Month 2, 6, 12, 18</title>
        <description>Toxin B antibodies were measured using neutralization assay.</description>
        <time_frame>Day 1, 30, 37, 187 and Month 2, 6, 12, 18</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for for Toxin B at Day 1, 30, 37, 187 and Month 2, 6, 12, 18</title>
          <description>Toxin B antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.5" upper_limit="13.0"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0.7" upper_limit="6.2"/>
                    <measurement group_id="O3" value="4.4" lower_limit="1.8" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="25.9" lower_limit="19.4" upper_limit="33.4"/>
                    <measurement group_id="O3" value="36.9" lower_limit="29.4" upper_limit="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.5" upper_limit="13.0"/>
                    <measurement group_id="O2" value="28.8" lower_limit="22.0" upper_limit="36.4"/>
                    <measurement group_id="O3" value="38.2" lower_limit="30.6" upper_limit="46.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="1.2" upper_limit="15.7"/>
                    <measurement group_id="O2" value="28.8" lower_limit="22.0" upper_limit="36.4"/>
                    <measurement group_id="O3" value="36.7" lower_limit="29.2" upper_limit="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="19.6" lower_limit="13.8" upper_limit="26.6"/>
                    <measurement group_id="O3" value="27.8" lower_limit="21.0" upper_limit="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="58.0" lower_limit="50.0" upper_limit="65.7"/>
                    <measurement group_id="O3" value="63.9" lower_limit="55.9" upper_limit="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="1.2" upper_limit="16.2"/>
                    <measurement group_id="O2" value="44.4" lower_limit="36.5" upper_limit="52.4"/>
                    <measurement group_id="O3" value="56.8" lower_limit="48.6" upper_limit="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="2.2" upper_limit="18.9"/>
                    <measurement group_id="O2" value="34.4" lower_limit="27.0" upper_limit="42.5"/>
                    <measurement group_id="O3" value="47.4" lower_limit="39.2" upper_limit="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Day 1, 30, 37, 187 and Month 2, 6, 12, 18</title>
        <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
        <time_frame>Day 1, 30, 37, 187 and Month 2, 6, 12, 18</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Day 1, 30, 37, 187 and Month 2, 6, 12, 18</title>
          <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="10.5" lower_limit="6.2" upper_limit="16.3"/>
                    <measurement group_id="O3" value="13.4" lower_limit="8.5" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="19.6" lower_limit="13.8" upper_limit="26.6"/>
                    <measurement group_id="O3" value="27.4" lower_limit="20.6" upper_limit="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="20.2" lower_limit="14.4" upper_limit="27.2"/>
                    <measurement group_id="O3" value="27.8" lower_limit="21.0" upper_limit="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="10.4" lower_limit="6.2" upper_limit="16.2"/>
                    <measurement group_id="O3" value="11.4" lower_limit="6.9" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="54.9" lower_limit="46.9" upper_limit="62.8"/>
                    <measurement group_id="O3" value="63.3" lower_limit="55.3" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                    <measurement group_id="O2" value="40.6" lower_limit="32.9" upper_limit="48.7"/>
                    <measurement group_id="O3" value="50.3" lower_limit="42.2" upper_limit="58.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="26.6" lower_limit="19.8" upper_limit="34.3"/>
                    <measurement group_id="O3" value="32.9" lower_limit="25.5" upper_limit="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 1, 8 and 30 Regimen: Geometric Mean Concentration of Toxin A Specific Neutralizing Antibody Levels at Day 1, 8, 15, 30, 37 and Month 2, 4, 7, 13</title>
        <description>Geometric mean concentration (GMC) of toxin A specific antibody levels was calculated using back transformations of the logarithmically transformed means of assay results. Confidence interval (CI) for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of concentrations.</description>
        <time_frame>Day 1, 8, 15, 30, 37 and Month 2, 4, 7, 13</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Geometric Mean Concentration of Toxin A Specific Neutralizing Antibody Levels at Day 1, 8, 15, 30, 37 and Month 2, 4, 7, 13</title>
          <description>Geometric mean concentration (GMC) of toxin A specific antibody levels was calculated using back transformations of the logarithmically transformed means of assay results. Confidence interval (CI) for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of concentrations.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations.</population>
          <units>neutralization units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="80.4" upper_limit="91.3"/>
                    <measurement group_id="O2" value="83" lower_limit="80.4" upper_limit="85.2"/>
                    <measurement group_id="O3" value="85" lower_limit="81.8" upper_limit="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="82.0" upper_limit="95.3"/>
                    <measurement group_id="O2" value="98" lower_limit="87.3" upper_limit="110.7"/>
                    <measurement group_id="O3" value="104" lower_limit="90.7" upper_limit="119.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="78.1" upper_limit="84.5"/>
                    <measurement group_id="O2" value="143" lower_limit="121.3" upper_limit="169.1"/>
                    <measurement group_id="O3" value="192" lower_limit="152.9" upper_limit="241.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="82.7" upper_limit="96.3"/>
                    <measurement group_id="O2" value="168" lower_limit="141.2" upper_limit="200.1"/>
                    <measurement group_id="O3" value="230" lower_limit="186.8" upper_limit="282.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102" lower_limit="88.4" upper_limit="118.7"/>
                    <measurement group_id="O2" value="368" lower_limit="314.6" upper_limit="431.4"/>
                    <measurement group_id="O3" value="556" lower_limit="480.0" upper_limit="644.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="85.7" upper_limit="105.5"/>
                    <measurement group_id="O2" value="295" lower_limit="255.3" upper_limit="340.4"/>
                    <measurement group_id="O3" value="484" lower_limit="415.9" upper_limit="562.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="79.0" upper_limit="90.6"/>
                    <measurement group_id="O2" value="153" lower_limit="133.8" upper_limit="175.7"/>
                    <measurement group_id="O3" value="238" lower_limit="206.5" upper_limit="274.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="78.1" upper_limit="84.8"/>
                    <measurement group_id="O2" value="118" lower_limit="105.0" upper_limit="133.1"/>
                    <measurement group_id="O3" value="166" lower_limit="143.7" upper_limit="191.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="80.9" upper_limit="96.8"/>
                    <measurement group_id="O2" value="105" lower_limit="94.7" upper_limit="116.5"/>
                    <measurement group_id="O3" value="138" lower_limit="119.9" upper_limit="159.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 1, 8 and 30 Regimen: Geometric Mean Concentration of Toxin B Specific Neutralizing Antibody Levels at Day 1, 8, 15, 30, 37 and Month 2, 4, 7, 13</title>
        <description>GMC of toxin B specific antibody levels was calculated using back transformations of the logarithmically transformed means of assay results. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of concentrations.</description>
        <time_frame>Day 1, 8, 15, 30, 37 and Month 2, 4, 7, 13</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Geometric Mean Concentration of Toxin B Specific Neutralizing Antibody Levels at Day 1, 8, 15, 30, 37 and Month 2, 4, 7, 13</title>
          <description>GMC of toxin B specific antibody levels was calculated using back transformations of the logarithmically transformed means of assay results. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of concentrations.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations.</population>
          <units>neutralization units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193" lower_limit="150.5" upper_limit="247.2"/>
                    <measurement group_id="O2" value="187" lower_limit="162.8" upper_limit="215.4"/>
                    <measurement group_id="O3" value="188" lower_limit="162.5" upper_limit="217.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" lower_limit="149.6" upper_limit="241.6"/>
                    <measurement group_id="O2" value="273" lower_limit="215.5" upper_limit="345.1"/>
                    <measurement group_id="O3" value="290" lower_limit="226.5" upper_limit="372.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" lower_limit="148.7" upper_limit="241.7"/>
                    <measurement group_id="O2" value="807" lower_limit="551.7" upper_limit="1180.9"/>
                    <measurement group_id="O3" value="1091" lower_limit="720.1" upper_limit="1652.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211" lower_limit="152.7" upper_limit="292.9"/>
                    <measurement group_id="O2" value="705" lower_limit="498.4" upper_limit="997.0"/>
                    <measurement group_id="O3" value="1029" lower_limit="688.4" upper_limit="1539.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180" lower_limit="142.3" upper_limit="227.1"/>
                    <measurement group_id="O2" value="728" lower_limit="520.8" upper_limit="1017.4"/>
                    <measurement group_id="O3" value="1219" lower_limit="831.1" upper_limit="1787.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188" lower_limit="147.0" upper_limit="239.3"/>
                    <measurement group_id="O2" value="676" lower_limit="490.0" upper_limit="933.6"/>
                    <measurement group_id="O3" value="1125" lower_limit="786.5" upper_limit="1608.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181" lower_limit="143.9" upper_limit="226.9"/>
                    <measurement group_id="O2" value="513" lower_limit="389.0" upper_limit="676.7"/>
                    <measurement group_id="O3" value="836" lower_limit="608.1" upper_limit="1150.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179" lower_limit="144.1" upper_limit="222.7"/>
                    <measurement group_id="O2" value="475" lower_limit="368.3" upper_limit="612.2"/>
                    <measurement group_id="O3" value="755" lower_limit="559.9" upper_limit="1018.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178" lower_limit="142.6" upper_limit="221.5"/>
                    <measurement group_id="O2" value="447" lower_limit="350.1" upper_limit="569.8"/>
                    <measurement group_id="O3" value="828" lower_limit="618.2" upper_limit="1110.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 0, 1 and 6 Regimen: Geometric Mean Concentration of Toxin A Specific Neutralizing Antibody Levels at Day 1, 30, 37, 187 and Month 2, 6, 7, 12, 18</title>
        <description>GMC of toxin A specific antibody levels was calculated using back transformations of the logarithmically transformed means of assay results. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of concentrations.</description>
        <time_frame>Day 1, 30, 37, 187 and Month 2, 6, 7, 12, 18</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Geometric Mean Concentration of Toxin A Specific Neutralizing Antibody Levels at Day 1, 30, 37, 187 and Month 2, 6, 7, 12, 18</title>
          <description>GMC of toxin A specific antibody levels was calculated using back transformations of the logarithmically transformed means of assay results. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of concentrations.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
          <units>neutralization units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="78.3" upper_limit="88.9"/>
                    <measurement group_id="O2" value="85" lower_limit="82.3" upper_limit="88.6"/>
                    <measurement group_id="O3" value="87" lower_limit="83.1" upper_limit="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="77.9" upper_limit="85.6"/>
                    <measurement group_id="O2" value="137" lower_limit="115.2" upper_limit="163.7"/>
                    <measurement group_id="O3" value="149" lower_limit="122.7" upper_limit="181.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="85.1" upper_limit="102.6"/>
                    <measurement group_id="O2" value="231" lower_limit="191.6" upper_limit="277.3"/>
                    <measurement group_id="O3" value="329" lower_limit="270.6" upper_limit="400.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="78.1" upper_limit="89.0"/>
                    <measurement group_id="O2" value="214" lower_limit="180.7" upper_limit="253.8"/>
                    <measurement group_id="O3" value="301" lower_limit="250.6" upper_limit="362.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="79.0" upper_limit="89.6"/>
                    <measurement group_id="O2" value="115" lower_limit="101.5" upper_limit="129.5"/>
                    <measurement group_id="O3" value="136" lower_limit="116.4" upper_limit="158.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="77.9" upper_limit="82.3"/>
                    <measurement group_id="O2" value="500" lower_limit="422.6" upper_limit="591.3"/>
                    <measurement group_id="O3" value="744" lower_limit="618.9" upper_limit="894.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="81.9" upper_limit="99.0"/>
                    <measurement group_id="O2" value="1245" lower_limit="1102.2" upper_limit="1405.6"/>
                    <measurement group_id="O3" value="1380" lower_limit="1198.6" upper_limit="1589.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="79.6" upper_limit="99.2"/>
                    <measurement group_id="O2" value="378" lower_limit="323.2" upper_limit="441.9"/>
                    <measurement group_id="O3" value="473" lower_limit="402.1" upper_limit="556.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="81.5" upper_limit="97.8"/>
                    <measurement group_id="O2" value="214" lower_limit="182.1" upper_limit="250.7"/>
                    <measurement group_id="O3" value="257" lower_limit="216.0" upper_limit="305.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 0, 1 and 6 Regimen: Geometric Mean Concentration of Toxin B Specific Neutralizing Antibody Levels at Day 1, 30, 37, 187 and Month 2, 6, 7, 12, 18</title>
        <description>GMC of toxin B specific antibody levels was calculated using back transformations of the logarithmically transformed means of assay results. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of concentrations.</description>
        <time_frame>Day 1, 30, 37, 187 and Month 2, 6, 7, 12, 18</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Geometric Mean Concentration of Toxin B Specific Neutralizing Antibody Levels at Day 1, 30, 37, 187 and Month 2, 6, 7, 12, 18</title>
          <description>GMC of toxin B specific antibody levels was calculated using back transformations of the logarithmically transformed means of assay results. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of concentrations.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
          <units>neutralization units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231" lower_limit="172.6" upper_limit="308.6"/>
                    <measurement group_id="O2" value="177" lower_limit="154.7" upper_limit="201.5"/>
                    <measurement group_id="O3" value="191" lower_limit="163.4" upper_limit="223.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209" lower_limit="159.1" upper_limit="273.9"/>
                    <measurement group_id="O2" value="570" lower_limit="410.2" upper_limit="791.1"/>
                    <measurement group_id="O3" value="909" lower_limit="624.3" upper_limit="1324.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218" lower_limit="164.7" upper_limit="288.6"/>
                    <measurement group_id="O2" value="662" lower_limit="472.4" upper_limit="928.0"/>
                    <measurement group_id="O3" value="1071" lower_limit="738.0" upper_limit="1553.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216" lower_limit="160.7" upper_limit="289.4"/>
                    <measurement group_id="O2" value="656" lower_limit="473.1" upper_limit="909.0"/>
                    <measurement group_id="O3" value="1029" lower_limit="718.2" upper_limit="1473.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214" lower_limit="163.4" upper_limit="279.8"/>
                    <measurement group_id="O2" value="447" lower_limit="340.7" upper_limit="586.7"/>
                    <measurement group_id="O3" value="702" lower_limit="515.4" upper_limit="955.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199" lower_limit="155.0" upper_limit="255.1"/>
                    <measurement group_id="O2" value="2805" lower_limit="2162.7" upper_limit="3636.9"/>
                    <measurement group_id="O3" value="4669" lower_limit="3585.5" upper_limit="6079.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229" lower_limit="168.0" upper_limit="310.9"/>
                    <measurement group_id="O2" value="6255" lower_limit="4971.0" upper_limit="7870.5"/>
                    <measurement group_id="O3" value="9549" lower_limit="7691.2" upper_limit="11856.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247" lower_limit="174.2" upper_limit="349.4"/>
                    <measurement group_id="O2" value="1799" lower_limit="1431.5" upper_limit="2260.1"/>
                    <measurement group_id="O3" value="2993" lower_limit="2365.7" upper_limit="3786.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263" lower_limit="187.4" upper_limit="370.1"/>
                    <measurement group_id="O2" value="1248" lower_limit="970.6" upper_limit="1604.0"/>
                    <measurement group_id="O3" value="2178" lower_limit="1661.6" upper_limit="2856.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 1, 8 and 30 Regimen: Geometric Mean Fold Rise in Toxin A Specific Neutralizing Antibody Levels From Baseline at Day 8, 15, 30, 37 and Month 2, 4, 7, 13</title>
        <description>Geometric mean fold rise (GMFR) in toxin A specific antibody levels was calculated using back transformations of the logarithmically transformed means of fold rise from baseline with assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</description>
        <time_frame>Day 8, 15, 30, 37 and Month 2, 4, 7, 13</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Geometric Mean Fold Rise in Toxin A Specific Neutralizing Antibody Levels From Baseline at Day 8, 15, 30, 37 and Month 2, 4, 7, 13</title>
          <description>Geometric mean fold rise (GMFR) in toxin A specific antibody levels was calculated using back transformations of the logarithmically transformed means of fold rise from baseline with assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.95" upper_limit="1.13"/>
                    <measurement group_id="O2" value="1.19" lower_limit="1.06" upper_limit="1.33"/>
                    <measurement group_id="O3" value="1.22" lower_limit="1.07" upper_limit="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.89" upper_limit="1.01"/>
                    <measurement group_id="O2" value="1.73" lower_limit="1.47" upper_limit="2.04"/>
                    <measurement group_id="O3" value="2.27" lower_limit="1.80" upper_limit="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="0.95" upper_limit="1.14"/>
                    <measurement group_id="O2" value="2.03" lower_limit="1.71" upper_limit="2.41"/>
                    <measurement group_id="O3" value="2.72" lower_limit="2.20" upper_limit="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" lower_limit="1.03" upper_limit="1.39"/>
                    <measurement group_id="O2" value="4.45" lower_limit="3.81" upper_limit="5.20"/>
                    <measurement group_id="O3" value="6.56" lower_limit="5.65" upper_limit="7.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" lower_limit="0.99" upper_limit="1.25"/>
                    <measurement group_id="O2" value="3.56" lower_limit="3.09" upper_limit="4.10"/>
                    <measurement group_id="O3" value="5.71" lower_limit="4.89" upper_limit="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.91" upper_limit="1.06"/>
                    <measurement group_id="O2" value="1.85" lower_limit="1.62" upper_limit="2.12"/>
                    <measurement group_id="O3" value="2.81" lower_limit="2.44" upper_limit="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.89" upper_limit="1.01"/>
                    <measurement group_id="O2" value="1.43" lower_limit="1.27" upper_limit="1.60"/>
                    <measurement group_id="O3" value="1.95" lower_limit="1.68" upper_limit="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.92" upper_limit="1.15"/>
                    <measurement group_id="O2" value="1.26" lower_limit="1.14" upper_limit="1.40"/>
                    <measurement group_id="O3" value="1.64" lower_limit="1.42" upper_limit="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 1, 8 and 30 Regimen: Geometric Mean Fold Rise in Toxin B Specific Neutralizing Antibody Levels From Baseline at Day 8, 15, 30, 37 and Month 2, 4, 7, 13</title>
        <description>GMFR in toxin B specific antibody levels was calculated using back transformations of the logarithmically transformed means of fold rise from baseline with assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</description>
        <time_frame>Day 8, 15, 30, 37 and Month 2, 4, 7, 13</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations. Here, N= number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Geometric Mean Fold Rise in Toxin B Specific Neutralizing Antibody Levels From Baseline at Day 8, 15, 30, 37 and Month 2, 4, 7, 13</title>
          <description>GMFR in toxin B specific antibody levels was calculated using back transformations of the logarithmically transformed means of fold rise from baseline with assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations. Here, N= number of participants evaluable for this outcome measure.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.94" upper_limit="1.04"/>
                    <measurement group_id="O2" value="1.46" lower_limit="1.24" upper_limit="1.72"/>
                    <measurement group_id="O3" value="1.55" lower_limit="1.31" upper_limit="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="0.94" upper_limit="1.03"/>
                    <measurement group_id="O2" value="4.31" lower_limit="3.17" upper_limit="5.87"/>
                    <measurement group_id="O3" value="5.86" lower_limit="4.07" upper_limit="8.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" lower_limit="0.86" upper_limit="1.39"/>
                    <measurement group_id="O2" value="3.76" lower_limit="2.87" upper_limit="4.94"/>
                    <measurement group_id="O3" value="5.53" lower_limit="3.89" upper_limit="7.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.84" upper_limit="1.04"/>
                    <measurement group_id="O2" value="3.89" lower_limit="2.99" upper_limit="5.05"/>
                    <measurement group_id="O3" value="6.57" lower_limit="4.74" upper_limit="9.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.90" upper_limit="1.05"/>
                    <measurement group_id="O2" value="3.61" lower_limit="2.82" upper_limit="4.63"/>
                    <measurement group_id="O3" value="6.06" lower_limit="4.50" upper_limit="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.84" upper_limit="1.02"/>
                    <measurement group_id="O2" value="2.73" lower_limit="2.23" upper_limit="3.35"/>
                    <measurement group_id="O3" value="4.55" lower_limit="3.53" upper_limit="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.88" upper_limit="1.04"/>
                    <measurement group_id="O2" value="2.52" lower_limit="2.09" upper_limit="3.03"/>
                    <measurement group_id="O3" value="4.05" lower_limit="3.20" upper_limit="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.87" upper_limit="1.04"/>
                    <measurement group_id="O2" value="2.40" lower_limit="2.00" upper_limit="2.89"/>
                    <measurement group_id="O3" value="4.44" lower_limit="3.46" upper_limit="5.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 0, 1 and 6 Regimen: Geometric Mean Fold Rise in Toxin A Specific Neutralizing Antibody Levels From Baseline at Day 30, 37, 187 and Month 2, 6, 7, 12, 18</title>
        <description>GMFR in toxin A specific antibody levels was calculated using back transformations of the logarithmically transformed means of fold rise from baseline with assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</description>
        <time_frame>Day 30, 37, 187 and Month 2, 6, 7, 12, 18</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Geometric Mean Fold Rise in Toxin A Specific Neutralizing Antibody Levels From Baseline at Day 30, 37, 187 and Month 2, 6, 7, 12, 18</title>
          <description>GMFR in toxin A specific antibody levels was calculated using back transformations of the logarithmically transformed means of fold rise from baseline with assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="0.90" upper_limit="1.06"/>
                    <measurement group_id="O2" value="1.61" lower_limit="1.35" upper_limit="1.91"/>
                    <measurement group_id="O3" value="1.71" lower_limit="1.41" upper_limit="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="0.99" upper_limit="1.26"/>
                    <measurement group_id="O2" value="2.70" lower_limit="2.25" upper_limit="3.24"/>
                    <measurement group_id="O3" value="3.78" lower_limit="3.10" upper_limit="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.91" upper_limit="1.10"/>
                    <measurement group_id="O2" value="2.51" lower_limit="2.12" upper_limit="2.97"/>
                    <measurement group_id="O3" value="3.46" lower_limit="2.88" upper_limit="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.92" upper_limit="1.11"/>
                    <measurement group_id="O2" value="1.34" lower_limit="1.19" upper_limit="1.52"/>
                    <measurement group_id="O3" value="1.56" lower_limit="1.34" upper_limit="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.89" upper_limit="1.03"/>
                    <measurement group_id="O2" value="5.85" lower_limit="4.92" upper_limit="6.95"/>
                    <measurement group_id="O3" value="8.54" lower_limit="7.08" upper_limit="10.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="0.96" upper_limit="1.22"/>
                    <measurement group_id="O2" value="14.58" lower_limit="12.82" upper_limit="16.58"/>
                    <measurement group_id="O3" value="15.85" lower_limit="13.70" upper_limit="18.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" lower_limit="0.93" upper_limit="1.21"/>
                    <measurement group_id="O2" value="4.42" lower_limit="3.77" upper_limit="5.19"/>
                    <measurement group_id="O3" value="5.45" lower_limit="4.62" upper_limit="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="0.95" upper_limit="1.20"/>
                    <measurement group_id="O2" value="2.51" lower_limit="2.14" upper_limit="2.95"/>
                    <measurement group_id="O3" value="2.95" lower_limit="2.49" upper_limit="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 0, 1 and 6 Regimen: Geometric Mean Fold Rise in Toxin B Specific Neutralizing Antibody Levels From Baseline at Day 30, 37, 187 and Month 2, 6, 7, 12, 18</title>
        <description>GMFR for toxin B specific antibody levels was calculated using back transformations of the logarithmically transformed means of fold rise from baseline with assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</description>
        <time_frame>Day 30, 37, 187 and Month 2, 6, 7, 12, 18</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Geometric Mean Fold Rise in Toxin B Specific Neutralizing Antibody Levels From Baseline at Day 30, 37, 187 and Month 2, 6, 7, 12, 18</title>
          <description>GMFR for toxin B specific antibody levels was calculated using back transformations of the logarithmically transformed means of fold rise from baseline with assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.74" upper_limit="1.10"/>
                    <measurement group_id="O2" value="3.28" lower_limit="2.48" upper_limit="4.35"/>
                    <measurement group_id="O3" value="4.75" lower_limit="3.47" upper_limit="6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="0.79" upper_limit="1.13"/>
                    <measurement group_id="O2" value="3.75" lower_limit="2.85" upper_limit="4.94"/>
                    <measurement group_id="O3" value="5.59" lower_limit="4.16" upper_limit="7.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.74" upper_limit="1.18"/>
                    <measurement group_id="O2" value="3.71" lower_limit="2.83" upper_limit="4.87"/>
                    <measurement group_id="O3" value="5.38" lower_limit="4.05" upper_limit="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.76" upper_limit="1.13"/>
                    <measurement group_id="O2" value="2.53" lower_limit="2.06" upper_limit="3.12"/>
                    <measurement group_id="O3" value="3.67" lower_limit="2.90" upper_limit="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="0.72" upper_limit="1.03"/>
                    <measurement group_id="O2" value="15.85" lower_limit="12.54" upper_limit="20.05"/>
                    <measurement group_id="O3" value="24.44" lower_limit="19.14" upper_limit="31.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.81" upper_limit="1.21"/>
                    <measurement group_id="O2" value="35.43" lower_limit="28.35" upper_limit="44.27"/>
                    <measurement group_id="O3" value="49.98" lower_limit="40.24" upper_limit="62.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="0.84" upper_limit="1.30"/>
                    <measurement group_id="O2" value="10.19" lower_limit="8.32" upper_limit="12.49"/>
                    <measurement group_id="O3" value="15.54" lower_limit="12.61" upper_limit="19.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" lower_limit="0.90" upper_limit="1.39"/>
                    <measurement group_id="O2" value="7.07" lower_limit="5.69" upper_limit="8.77"/>
                    <measurement group_id="O3" value="11.21" lower_limit="8.85" upper_limit="14.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin A Specific Antibody Levels at Day 8, 15, 30, 37 and Month 2, 4, 7, 13</title>
        <description>Toxin A antibodies were measured using neutralization assay.</description>
        <time_frame>Day 8, 15, 30, 37 and Month 2, 4, 7, 13</time_frame>
        <population>Evaluable immunogenicity population: All eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations. N= number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin A Specific Antibody Levels at Day 8, 15, 30, 37 and Month 2, 4, 7, 13</title>
          <description>Toxin A antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: All eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations. N= number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.3" upper_limit="7.5"/>
                    <measurement group_id="O3" value="4.9" lower_limit="2.1" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="2.9" lower_limit="1.0" upper_limit="6.7"/>
                    <measurement group_id="O3" value="4.3" lower_limit="1.7" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.6" upper_limit="5.9"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.6" upper_limit="5.9"/>
                    <measurement group_id="O3" value="2.4" lower_limit="0.7" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="14.6" lower_limit="9.7" upper_limit="20.8"/>
                    <measurement group_id="O3" value="19.6" lower_limit="13.8" upper_limit="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="9.9" lower_limit="5.9" upper_limit="15.4"/>
                    <measurement group_id="O3" value="17.8" lower_limit="12.3" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="5.8" lower_limit="2.8" upper_limit="10.5"/>
                    <measurement group_id="O3" value="14.1" lower_limit="9.2" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="4.7" lower_limit="2.0" upper_limit="9.0"/>
                    <measurement group_id="O3" value="9.2" lower_limit="5.2" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="17.5" lower_limit="12.2" upper_limit="24.1"/>
                    <measurement group_id="O3" value="25.8" lower_limit="19.2" upper_limit="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="8.2" lower_limit="4.5" upper_limit="13.4"/>
                    <measurement group_id="O3" value="17.2" lower_limit="11.7" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="5.8" lower_limit="2.8" upper_limit="10.5"/>
                    <measurement group_id="O3" value="13.5" lower_limit="8.7" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="5.3" lower_limit="2.4" upper_limit="9.8"/>
                    <measurement group_id="O3" value="8.6" lower_limit="4.8" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="1.1" upper_limit="14.9"/>
                    <measurement group_id="O2" value="46.8" lower_limit="39.1" upper_limit="54.6"/>
                    <measurement group_id="O3" value="65.2" lower_limit="57.4" upper_limit="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="25.1" lower_limit="18.8" upper_limit="32.3"/>
                    <measurement group_id="O3" value="40.9" lower_limit="33.3" upper_limit="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="8.8" lower_limit="5.0" upper_limit="14.1"/>
                    <measurement group_id="O3" value="14.0" lower_limit="9.1" upper_limit="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.3" upper_limit="7.5"/>
                    <measurement group_id="O3" value="8.5" lower_limit="4.7" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.0" upper_limit="9.6"/>
                    <measurement group_id="O2" value="32.7" lower_limit="25.8" upper_limit="40.3"/>
                    <measurement group_id="O3" value="59.1" lower_limit="51.2" upper_limit="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="18.1" lower_limit="12.7" upper_limit="24.7"/>
                    <measurement group_id="O3" value="31.1" lower_limit="24.1" upper_limit="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="5.8" lower_limit="2.8" upper_limit="10.5"/>
                    <measurement group_id="O3" value="12.8" lower_limit="8.1" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.3" upper_limit="7.5"/>
                    <measurement group_id="O3" value="6.7" lower_limit="3.4" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="13.5" lower_limit="8.8" upper_limit="19.6"/>
                    <measurement group_id="O3" value="24.5" lower_limit="18.1" upper_limit="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="7.1" lower_limit="3.7" upper_limit="12.0"/>
                    <measurement group_id="O3" value="12.9" lower_limit="8.2" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="4.1" lower_limit="1.7" upper_limit="8.3"/>
                    <measurement group_id="O3" value="5.5" lower_limit="2.6" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.1" upper_limit="4.2"/>
                    <measurement group_id="O3" value="2.5" lower_limit="0.7" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="9.0" lower_limit="5.1" upper_limit="14.5"/>
                    <measurement group_id="O3" value="16.5" lower_limit="11.0" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="5.4" lower_limit="2.5" upper_limit="10.0"/>
                    <measurement group_id="O3" value="10.1" lower_limit="5.9" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.4" upper_limit="5.2"/>
                    <measurement group_id="O3" value="5.7" lower_limit="2.6" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.2" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O2" value="6.3" lower_limit="3.1" upper_limit="11.3"/>
                    <measurement group_id="O3" value="16.2" lower_limit="10.8" upper_limit="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="3.8" lower_limit="1.4" upper_limit="8.1"/>
                    <measurement group_id="O3" value="9.7" lower_limit="5.6" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O3" value="3.2" lower_limit="1.1" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin B Specific Antibody Levels at Day 8, 15, 30, 37 and Month 2, 4, 7, 13</title>
        <description>Toxin B antibodies were measured using neutralization assay.</description>
        <time_frame>Day 8, 15, 30, 37 and Month 2, 4, 7, 13</time_frame>
        <population>Evaluable immunogenicity population: All eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations. N= number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin B Specific Antibody Levels at Day 8, 15, 30, 37 and Month 2, 4, 7, 13</title>
          <description>Toxin B antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: All eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations. N= number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="11.7" lower_limit="7.3" upper_limit="17.5"/>
                    <measurement group_id="O3" value="14.6" lower_limit="9.6" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="8.2" lower_limit="4.5" upper_limit="13.4"/>
                    <measurement group_id="O3" value="8.5" lower_limit="4.7" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="4.7" lower_limit="2.0" upper_limit="9.0"/>
                    <measurement group_id="O3" value="4.9" lower_limit="2.1" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.3" upper_limit="7.5"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="36.8" lower_limit="29.6" upper_limit="44.5"/>
                    <measurement group_id="O3" value="41.1" lower_limit="33.5" upper_limit="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="33.3" lower_limit="26.3" upper_limit="40.9"/>
                    <measurement group_id="O3" value="38.7" lower_limit="31.1" upper_limit="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="26.3" lower_limit="19.9" upper_limit="33.6"/>
                    <measurement group_id="O3" value="35.0" lower_limit="27.7" upper_limit="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="20.5" lower_limit="14.7" upper_limit="27.3"/>
                    <measurement group_id="O3" value="29.4" lower_limit="22.6" upper_limit="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.0" upper_limit="9.6"/>
                    <measurement group_id="O2" value="39.2" lower_limit="31.8" upper_limit="46.9"/>
                    <measurement group_id="O3" value="42.3" lower_limit="34.6" upper_limit="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.0" upper_limit="9.6"/>
                    <measurement group_id="O2" value="33.3" lower_limit="26.3" upper_limit="40.9"/>
                    <measurement group_id="O3" value="39.9" lower_limit="32.3" upper_limit="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.0" upper_limit="9.6"/>
                    <measurement group_id="O2" value="22.8" lower_limit="16.7" upper_limit="29.8"/>
                    <measurement group_id="O3" value="37.4" lower_limit="30.0" upper_limit="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.0" upper_limit="9.6"/>
                    <measurement group_id="O2" value="17.0" lower_limit="11.7" upper_limit="23.4"/>
                    <measurement group_id="O3" value="27.6" lower_limit="20.9" upper_limit="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="41.5" lower_limit="34.0" upper_limit="49.3"/>
                    <measurement group_id="O3" value="46.3" lower_limit="38.5" upper_limit="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="33.9" lower_limit="26.9" upper_limit="41.5"/>
                    <measurement group_id="O3" value="40.2" lower_limit="32.7" upper_limit="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="24.0" lower_limit="17.8" upper_limit="31.1"/>
                    <measurement group_id="O3" value="37.2" lower_limit="29.8" upper_limit="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="16.4" lower_limit="11.2" upper_limit="22.8"/>
                    <measurement group_id="O3" value="27.4" lower_limit="20.8" upper_limit="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="39.2" lower_limit="31.8" upper_limit="46.9"/>
                    <measurement group_id="O3" value="46.3" lower_limit="38.5" upper_limit="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="32.2" lower_limit="25.2" upper_limit="39.7"/>
                    <measurement group_id="O3" value="38.4" lower_limit="30.9" upper_limit="46.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="22.8" lower_limit="16.7" upper_limit="29.8"/>
                    <measurement group_id="O3" value="34.1" lower_limit="26.9" upper_limit="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="14.6" lower_limit="9.7" upper_limit="20.8"/>
                    <measurement group_id="O3" value="24.4" lower_limit="18.0" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="35.9" lower_limit="28.7" upper_limit="43.6"/>
                    <measurement group_id="O3" value="42.3" lower_limit="34.6" upper_limit="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="23.5" lower_limit="17.4" upper_limit="30.6"/>
                    <measurement group_id="O3" value="34.4" lower_limit="27.1" upper_limit="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="14.7" lower_limit="9.7" upper_limit="20.9"/>
                    <measurement group_id="O3" value="25.8" lower_limit="19.2" upper_limit="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="5.9" lower_limit="2.9" upper_limit="10.6"/>
                    <measurement group_id="O3" value="16.6" lower_limit="11.2" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="34.9" lower_limit="27.7" upper_limit="42.7"/>
                    <measurement group_id="O3" value="45.6" lower_limit="37.6" upper_limit="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="19.9" lower_limit="14.1" upper_limit="26.8"/>
                    <measurement group_id="O3" value="30.4" lower_limit="23.3" upper_limit="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="8.4" lower_limit="4.7" upper_limit="13.7"/>
                    <measurement group_id="O3" value="20.3" lower_limit="14.3" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.4" upper_limit="5.2"/>
                    <measurement group_id="O3" value="13.3" lower_limit="8.4" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="35.4" lower_limit="28.0" upper_limit="43.4"/>
                    <measurement group_id="O3" value="46.8" lower_limit="38.7" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="17.7" lower_limit="12.1" upper_limit="24.6"/>
                    <measurement group_id="O3" value="30.5" lower_limit="23.4" upper_limit="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="10.8" lower_limit="6.4" upper_limit="16.7"/>
                    <measurement group_id="O3" value="20.8" lower_limit="14.7" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.2" upper_limit="4.5"/>
                    <measurement group_id="O3" value="14.9" lower_limit="9.7" upper_limit="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving&gt;=4,&gt;=8,&gt;=16,&gt;=32 Fold Rise From Baseline in Both Toxin A and Toxin B Specific Antibody Levels at Day 8, 15, 30, 37 and Month 2, 4, 7, 13</title>
        <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
        <time_frame>Day 8, 15, 30, 37 and Month 2, 4, 7, 13</time_frame>
        <population>Evaluable immunogenicity population: All eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations. N= number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Day 1, 8 and 30 Regimen</title>
            <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1, 8 and 30 Regimen: Percentage of Participants Achieving&gt;=4,&gt;=8,&gt;=16,&gt;=32 Fold Rise From Baseline in Both Toxin A and Toxin B Specific Antibody Levels at Day 8, 15, 30, 37 and Month 2, 4, 7, 13</title>
          <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: All eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 7 to 14 days after Vaccination 3 and had no major protocol violations. N= number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.3" upper_limit="7.5"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="2.9" lower_limit="1.0" upper_limit="6.7"/>
                    <measurement group_id="O3" value="1.8" lower_limit="0.4" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.6" upper_limit="5.9"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.1" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.4" upper_limit="5.0"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="12.3" lower_limit="7.8" upper_limit="18.2"/>
                    <measurement group_id="O3" value="17.2" lower_limit="11.7" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="7.6" lower_limit="4.1" upper_limit="12.6"/>
                    <measurement group_id="O3" value="14.7" lower_limit="9.7" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="4.7" lower_limit="2.0" upper_limit="9.0"/>
                    <measurement group_id="O3" value="9.8" lower_limit="5.7" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.3" upper_limit="7.5"/>
                    <measurement group_id="O3" value="4.9" lower_limit="2.1" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="13.5" lower_limit="8.7" upper_limit="19.5"/>
                    <measurement group_id="O3" value="20.2" lower_limit="14.4" upper_limit="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="7.0" lower_limit="3.7" upper_limit="11.9"/>
                    <measurement group_id="O3" value="14.1" lower_limit="9.2" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="4.1" lower_limit="1.7" upper_limit="8.3"/>
                    <measurement group_id="O3" value="11.0" lower_limit="6.7" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.3" upper_limit="7.5"/>
                    <measurement group_id="O3" value="5.5" lower_limit="2.6" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="25.1" lower_limit="18.8" upper_limit="32.3"/>
                    <measurement group_id="O3" value="36.0" lower_limit="28.6" upper_limit="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="14.6" lower_limit="9.7" upper_limit="20.8"/>
                    <measurement group_id="O3" value="25.6" lower_limit="19.1" upper_limit="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="6.4" lower_limit="3.3" upper_limit="11.2"/>
                    <measurement group_id="O3" value="11.6" lower_limit="7.1" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.6" upper_limit="5.9"/>
                    <measurement group_id="O3" value="6.7" lower_limit="3.4" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="21.6" lower_limit="15.7" upper_limit="28.6"/>
                    <measurement group_id="O3" value="34.8" lower_limit="27.5" upper_limit="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="11.7" lower_limit="7.3" upper_limit="17.5"/>
                    <measurement group_id="O3" value="21.3" lower_limit="15.3" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="2.9" lower_limit="1.0" upper_limit="6.7"/>
                    <measurement group_id="O3" value="10.4" lower_limit="6.2" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.6" upper_limit="5.9"/>
                    <measurement group_id="O3" value="5.5" lower_limit="2.5" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="8.8" lower_limit="5.0" upper_limit="14.1"/>
                    <measurement group_id="O3" value="19.0" lower_limit="13.3" upper_limit="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="4.1" lower_limit="1.7" upper_limit="8.3"/>
                    <measurement group_id="O3" value="9.2" lower_limit="5.2" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0.6" upper_limit="5.9"/>
                    <measurement group_id="O3" value="3.1" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.2"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.1" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="7.2" lower_limit="3.8" upper_limit="12.3"/>
                    <measurement group_id="O3" value="13.9" lower_limit="8.9" upper_limit="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1.3" upper_limit="7.7"/>
                    <measurement group_id="O3" value="7.0" lower_limit="3.5" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O3" value="3.2" lower_limit="1.0" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="5.1" lower_limit="2.2" upper_limit="9.7"/>
                    <measurement group_id="O3" value="14.3" lower_limit="9.2" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0.7" upper_limit="6.4"/>
                    <measurement group_id="O3" value="6.5" lower_limit="3.2" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.2" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin A Specific Antibody Levels at Day 30, 37, 187 and Month 2, 6, 7, 12, 18</title>
        <description>Toxin A antibodies were measured using neutralization assay.</description>
        <time_frame>Day 30, 37, 187 and Month 2, 6, 7, 12, 18</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin A Specific Antibody Levels at Day 30, 37, 187 and Month 2, 6, 7, 12, 18</title>
          <description>Toxin A antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="14.2" lower_limit="9.2" upper_limit="20.5"/>
                    <measurement group_id="O3" value="14.0" lower_limit="9.0" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="12.3" lower_limit="7.7" upper_limit="18.4"/>
                    <measurement group_id="O3" value="11.5" lower_limit="6.9" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="6.8" lower_limit="3.4" upper_limit="11.8"/>
                    <measurement group_id="O3" value="10.2" lower_limit="5.9" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0.7" upper_limit="6.2"/>
                    <measurement group_id="O3" value="6.4" lower_limit="3.1" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="28.2" lower_limit="21.5" upper_limit="35.8"/>
                    <measurement group_id="O3" value="40.1" lower_limit="32.4" upper_limit="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="16.0" lower_limit="10.7" upper_limit="22.5"/>
                    <measurement group_id="O3" value="26.8" lower_limit="20.0" upper_limit="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="6.1" lower_limit="3.0" upper_limit="11.0"/>
                    <measurement group_id="O3" value="12.7" lower_limit="8.0" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="3.1" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="7.0" lower_limit="3.5" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="28.2" lower_limit="21.5" upper_limit="35.8"/>
                    <measurement group_id="O3" value="36.1" lower_limit="28.6" upper_limit="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="14.7" lower_limit="9.7" upper_limit="21.1"/>
                    <measurement group_id="O3" value="21.5" lower_limit="15.4" upper_limit="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="6.7" lower_limit="3.4" upper_limit="11.8"/>
                    <measurement group_id="O3" value="12.0" lower_limit="7.4" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0.7" upper_limit="6.2"/>
                    <measurement group_id="O3" value="7.0" lower_limit="3.5" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="9.2" lower_limit="5.2" upper_limit="14.7"/>
                    <measurement group_id="O3" value="12.7" lower_limit="7.9" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="6.1" lower_limit="3.0" upper_limit="11.0"/>
                    <measurement group_id="O3" value="10.1" lower_limit="5.9" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.1" upper_limit="4.4"/>
                    <measurement group_id="O3" value="5.1" lower_limit="2.2" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O3" value="2.5" lower_limit="0.7" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="63.0" lower_limit="55.0" upper_limit="70.4"/>
                    <measurement group_id="O3" value="71.5" lower_limit="63.8" upper_limit="78.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="43.8" lower_limit="36.1" upper_limit="51.8"/>
                    <measurement group_id="O3" value="55.7" lower_limit="47.6" upper_limit="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="16.7" lower_limit="11.3" upper_limit="23.3"/>
                    <measurement group_id="O3" value="32.9" lower_limit="25.7" upper_limit="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="5.6" lower_limit="2.6" upper_limit="10.3"/>
                    <measurement group_id="O3" value="13.3" lower_limit="8.4" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="91.4" lower_limit="86.0" upper_limit="95.2"/>
                    <measurement group_id="O3" value="91.8" lower_limit="86.3" upper_limit="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="76.7" lower_limit="69.4" upper_limit="82.9"/>
                    <measurement group_id="O3" value="78.5" lower_limit="71.2" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="47.2" lower_limit="39.4" upper_limit="55.2"/>
                    <measurement group_id="O3" value="56.3" lower_limit="48.2" upper_limit="64.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="20.2" lower_limit="14.4" upper_limit="27.2"/>
                    <measurement group_id="O3" value="21.5" lower_limit="15.4" upper_limit="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                    <measurement group_id="O2" value="50.6" lower_limit="42.6" upper_limit="58.6"/>
                    <measurement group_id="O3" value="61.3" lower_limit="53.1" upper_limit="69.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                    <measurement group_id="O2" value="27.5" lower_limit="20.7" upper_limit="35.1"/>
                    <measurement group_id="O3" value="40.6" lower_limit="32.8" upper_limit="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="9.4" lower_limit="5.3" upper_limit="15.0"/>
                    <measurement group_id="O3" value="14.2" lower_limit="9.1" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0.7" upper_limit="6.3"/>
                    <measurement group_id="O3" value="1.9" lower_limit="0.4" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="27.9" lower_limit="21.0" upper_limit="35.7"/>
                    <measurement group_id="O3" value="39.5" lower_limit="31.6" upper_limit="47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="13.6" lower_limit="8.6" upper_limit="20.1"/>
                    <measurement group_id="O3" value="20.4" lower_limit="14.3" upper_limit="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="5.8" lower_limit="2.7" upper_limit="10.8"/>
                    <measurement group_id="O3" value="7.2" lower_limit="3.7" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.2" upper_limit="4.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin B Specific Antibody Levels at Day 30, 37, 187 and Month 2, 6, 7, 12, 18</title>
        <description>Toxin A antibodies were measured using neutralization assay.</description>
        <time_frame>Day 30, 37, 187 and Month 2, 6, 7, 12, 18</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin B Specific Antibody Levels at Day 30, 37, 187 and Month 2, 6, 7, 12, 18</title>
          <description>Toxin A antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.5" upper_limit="13.0"/>
                    <measurement group_id="O2" value="34.0" lower_limit="26.7" upper_limit="41.8"/>
                    <measurement group_id="O3" value="43.3" lower_limit="35.4" upper_limit="51.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="29.6" lower_limit="22.7" upper_limit="37.3"/>
                    <measurement group_id="O3" value="38.9" lower_limit="31.2" upper_limit="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="21.6" lower_limit="15.5" upper_limit="28.7"/>
                    <measurement group_id="O3" value="30.6" lower_limit="23.5" upper_limit="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="16.7" lower_limit="11.3" upper_limit="23.3"/>
                    <measurement group_id="O3" value="20.4" lower_limit="14.4" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.5" upper_limit="13.0"/>
                    <measurement group_id="O2" value="36.8" lower_limit="29.4" upper_limit="44.7"/>
                    <measurement group_id="O3" value="47.8" lower_limit="39.7" upper_limit="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="30.7" lower_limit="23.7" upper_limit="38.4"/>
                    <measurement group_id="O3" value="42.7" lower_limit="34.8" upper_limit="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="23.9" lower_limit="17.6" upper_limit="31.2"/>
                    <measurement group_id="O3" value="33.1" lower_limit="25.8" upper_limit="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="18.4" lower_limit="12.8" upper_limit="25.2"/>
                    <measurement group_id="O3" value="22.3" lower_limit="16.0" upper_limit="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.5" upper_limit="13.0"/>
                    <measurement group_id="O2" value="37.4" lower_limit="30.0" upper_limit="45.3"/>
                    <measurement group_id="O3" value="47.5" lower_limit="39.5" upper_limit="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="32.5" lower_limit="25.4" upper_limit="40.3"/>
                    <measurement group_id="O3" value="39.9" lower_limit="32.2" upper_limit="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="23.3" lower_limit="17.1" upper_limit="30.6"/>
                    <measurement group_id="O3" value="29.7" lower_limit="22.7" upper_limit="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="16.6" lower_limit="11.2" upper_limit="23.2"/>
                    <measurement group_id="O3" value="23.4" lower_limit="17.1" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.5" upper_limit="13.0"/>
                    <measurement group_id="O2" value="30.1" lower_limit="23.1" upper_limit="37.7"/>
                    <measurement group_id="O3" value="41.1" lower_limit="33.4" upper_limit="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.5" upper_limit="13.0"/>
                    <measurement group_id="O2" value="21.5" lower_limit="15.4" upper_limit="28.6"/>
                    <measurement group_id="O3" value="32.3" lower_limit="25.1" upper_limit="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="13.5" lower_limit="8.7" upper_limit="19.7"/>
                    <measurement group_id="O3" value="21.5" lower_limit="15.4" upper_limit="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="6.7" lower_limit="3.4" upper_limit="11.8"/>
                    <measurement group_id="O3" value="12.0" lower_limit="7.4" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="79.0" lower_limit="71.9" upper_limit="85.0"/>
                    <measurement group_id="O3" value="87.3" lower_limit="81.1" upper_limit="92.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="68.5" lower_limit="60.8" upper_limit="75.6"/>
                    <measurement group_id="O3" value="78.5" lower_limit="71.2" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="52.5" lower_limit="44.5" upper_limit="60.4"/>
                    <measurement group_id="O3" value="63.3" lower_limit="55.3" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="32.1" lower_limit="25.0" upper_limit="39.9"/>
                    <measurement group_id="O3" value="46.2" lower_limit="38.2" upper_limit="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.5" upper_limit="13.0"/>
                    <measurement group_id="O2" value="92.0" lower_limit="86.7" upper_limit="95.7"/>
                    <measurement group_id="O3" value="93.7" lower_limit="88.7" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="84.7" lower_limit="78.2" upper_limit="89.8"/>
                    <measurement group_id="O3" value="90.5" lower_limit="84.8" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="76.1" lower_limit="68.8" upper_limit="82.4"/>
                    <measurement group_id="O3" value="83.5" lower_limit="76.8" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="55.8" lower_limit="47.9" upper_limit="63.6"/>
                    <measurement group_id="O3" value="66.5" lower_limit="58.5" upper_limit="73.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="0.5" upper_limit="13.5"/>
                    <measurement group_id="O2" value="75.0" lower_limit="67.6" upper_limit="81.5"/>
                    <measurement group_id="O3" value="85.8" lower_limit="79.3" upper_limit="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="0.5" upper_limit="13.5"/>
                    <measurement group_id="O2" value="59.4" lower_limit="51.3" upper_limit="67.1"/>
                    <measurement group_id="O3" value="73.5" lower_limit="65.9" upper_limit="80.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="0.5" upper_limit="13.5"/>
                    <measurement group_id="O2" value="39.4" lower_limit="31.8" upper_limit="47.4"/>
                    <measurement group_id="O3" value="51.6" lower_limit="43.5" upper_limit="59.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="18.1" lower_limit="12.5" upper_limit="25.0"/>
                    <measurement group_id="O3" value="27.1" lower_limit="20.3" upper_limit="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="2.2" upper_limit="18.9"/>
                    <measurement group_id="O2" value="66.9" lower_limit="58.9" upper_limit="74.2"/>
                    <measurement group_id="O3" value="78.3" lower_limit="70.9" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="0.5" upper_limit="13.5"/>
                    <measurement group_id="O2" value="44.2" lower_limit="36.2" upper_limit="52.4"/>
                    <measurement group_id="O3" value="60.5" lower_limit="52.3" upper_limit="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                    <measurement group_id="O2" value="29.2" lower_limit="22.2" upper_limit="37.1"/>
                    <measurement group_id="O3" value="40.1" lower_limit="32.3" upper_limit="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="13.0" lower_limit="8.1" upper_limit="19.3"/>
                    <measurement group_id="O3" value="23.0" lower_limit="16.6" upper_limit="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving&gt;=4,&gt;=8,&gt;=16,&gt;=32 Fold Rise From Baseline in Both Toxin A and Toxin B Antibody Levels at Day 30, 37, 187 and Month 2, 6, 7, 12, 18</title>
        <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
        <time_frame>Day 30, 37, 187 and Month 2, 6, 7, 12, 18</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Month 0, 1 and 6 Regimen</title>
            <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
            <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Month 0, 1 and 6 Regimen: Percentage of Participants Achieving&gt;=4,&gt;=8,&gt;=16,&gt;=32 Fold Rise From Baseline in Both Toxin A and Toxin B Antibody Levels at Day 30, 37, 187 and Month 2, 6, 7, 12, 18</title>
          <description>Toxin A and toxin B antibodies were measured using neutralization assay.</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received all 3 study vaccinations to which they were randomized, had at least 1 valid assay result from blood drawn within 20 to 45 days after Vaccination 3 and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="11.7" lower_limit="7.2" upper_limit="17.7"/>
                    <measurement group_id="O3" value="12.1" lower_limit="7.4" upper_limit="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="9.3" lower_limit="5.3" upper_limit="14.8"/>
                    <measurement group_id="O3" value="9.6" lower_limit="5.4" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="3.1" lower_limit="1.0" upper_limit="7.1"/>
                    <measurement group_id="O3" value="7.0" lower_limit="3.5" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O3" value="3.2" lower_limit="1.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="19.0" lower_limit="13.3" upper_limit="25.9"/>
                    <measurement group_id="O3" value="26.8" lower_limit="20.0" upper_limit="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="9.2" lower_limit="5.2" upper_limit="14.7"/>
                    <measurement group_id="O3" value="19.7" lower_limit="13.8" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="3.7" lower_limit="1.4" upper_limit="7.8"/>
                    <measurement group_id="O3" value="8.3" lower_limit="4.5" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.1" upper_limit="4.4"/>
                    <measurement group_id="O3" value="3.8" lower_limit="1.4" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="18.4" lower_limit="12.8" upper_limit="25.2"/>
                    <measurement group_id="O3" value="24.1" lower_limit="17.6" upper_limit="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="10.4" lower_limit="6.2" upper_limit="16.2"/>
                    <measurement group_id="O3" value="14.6" lower_limit="9.5" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="3.1" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="7.0" lower_limit="3.5" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.1" upper_limit="4.4"/>
                    <measurement group_id="O3" value="3.2" lower_limit="1.0" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="8.0" lower_limit="4.3" upper_limit="13.3"/>
                    <measurement group_id="O3" value="10.1" lower_limit="5.9" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0.7" upper_limit="6.2"/>
                    <measurement group_id="O3" value="6.3" lower_limit="3.1" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O3" value="2.5" lower_limit="0.7" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.2" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="58.6" lower_limit="50.6" upper_limit="66.3"/>
                    <measurement group_id="O3" value="69.6" lower_limit="61.8" upper_limit="76.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="39.5" lower_limit="31.9" upper_limit="47.5"/>
                    <measurement group_id="O3" value="50.6" lower_limit="42.6" upper_limit="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="11.1" lower_limit="6.7" upper_limit="17.0"/>
                    <measurement group_id="O3" value="27.2" lower_limit="20.4" upper_limit="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 187: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0.7" upper_limit="6.2"/>
                    <measurement group_id="O3" value="10.8" lower_limit="6.4" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="84.7" lower_limit="78.2" upper_limit="89.8"/>
                    <measurement group_id="O3" value="87.3" lower_limit="81.1" upper_limit="92.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="68.7" lower_limit="61.0" upper_limit="75.7"/>
                    <measurement group_id="O3" value="74.1" lower_limit="66.5" upper_limit="80.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="41.1" lower_limit="33.5" upper_limit="49.1"/>
                    <measurement group_id="O3" value="52.5" lower_limit="44.4" upper_limit="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="14.1" lower_limit="9.2" upper_limit="20.4"/>
                    <measurement group_id="O3" value="17.1" lower_limit="11.6" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="44.4" lower_limit="36.5" upper_limit="52.4"/>
                    <measurement group_id="O3" value="58.7" lower_limit="50.5" upper_limit="66.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="21.9" lower_limit="15.7" upper_limit="29.1"/>
                    <measurement group_id="O3" value="35.5" lower_limit="28.0" upper_limit="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="2.2" upper_limit="9.6"/>
                    <measurement group_id="O3" value="9.7" lower_limit="5.5" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.2" upper_limit="4.4"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.2" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: &gt;=4 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="23.4" lower_limit="16.9" upper_limit="30.9"/>
                    <measurement group_id="O3" value="36.2" lower_limit="28.6" upper_limit="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: &gt;=8 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="10.4" lower_limit="6.1" upper_limit="16.3"/>
                    <measurement group_id="O3" value="19.1" lower_limit="13.2" upper_limit="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: &gt;=16 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.9" lower_limit="1.4" upper_limit="8.3"/>
                    <measurement group_id="O3" value="3.9" lower_limit="1.5" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: &gt;=32 fold rise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</title>
        <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4</time_frame>
        <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Stage Endpoint</title>
            <description>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</title>
          <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</title>
        <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4</time_frame>
        <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Stage Endpoint</title>
            <description>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</title>
          <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</title>
        <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4</time_frame>
        <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Stage Endpoint</title>
            <description>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Prespecified Antibody Titer Level for Both Toxin A and Toxin B at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</title>
          <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration for Toxin A Specific Neutralizing Antibody Levels at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</title>
        <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4</time_frame>
        <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Stage Endpoint</title>
            <description>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration for Toxin A Specific Neutralizing Antibody Levels at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</title>
          <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration for Toxin B Specific Neutralizing Antibody Levels at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</title>
        <time_frame>day 8, 30; month 6, 12, 18, 24, 30, 36 after Vaccination 4</time_frame>
        <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Stage Endpoint</title>
            <description>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration for Toxin B Specific Neutralizing Antibody Levels at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</title>
          <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise in Toxin A Specific Neutralizing Antibody Levels From Baseline at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</title>
        <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4</time_frame>
        <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Stage Endpoint</title>
            <description>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise in Toxin A Specific Neutralizing Antibody Levels From Baseline at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</title>
          <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise in Toxin B Specific Neutralizing Antibody Levels From Baseline at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</title>
        <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4</time_frame>
        <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Stage Endpoint</title>
            <description>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise in Toxin B Specific Neutralizing Antibody Levels From Baseline at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</title>
          <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin A Specific Antibody Levels at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</title>
        <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4</time_frame>
        <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Stage Endpoint</title>
            <description>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin A Specific Antibody Levels at Day 8, 30 and Month 6, 12, 18, 24, 30, 36</title>
          <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin B Specific Antibody Levels at Day 8, 30, Month 6, 12, 18, 24, 30 and 36</title>
        <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36</time_frame>
        <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Stage Endpoint</title>
            <description>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving &gt;=4, &gt;=8, &gt;=16 and &gt;=32 Fold Rise From Baseline in Toxin B Specific Antibody Levels at Day 8, 30, Month 6, 12, 18, 24, 30 and 36</title>
          <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving&gt;=4,&gt;=8,&gt;=16,&gt;=32 Fold Rise From Baseline in Both Toxin A and Toxin B Antibody Levels at Day 8, 30, Month 6, 12, 18, 24, 30 and 36</title>
        <time_frame>Day 8, 30 and Month 6, 12, 18, 24, 30, 36</time_frame>
        <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Stage Endpoint</title>
            <description>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving&gt;=4,&gt;=8,&gt;=16,&gt;=32 Fold Rise From Baseline in Both Toxin A and Toxin B Antibody Levels at Day 8, 30, Month 6, 12, 18, 24, 30 and 36</title>
          <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Local Reactions by Severity Within 14 Days of Vaccination 4</title>
        <time_frame>within 14 days of Vaccination 4</time_frame>
        <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Stage Endpoint</title>
            <description>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Local Reactions by Severity Within 14 Days of Vaccination 4</title>
          <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Systemic Events by Severity Within 14 Days of Vaccination 4</title>
        <time_frame>within 14 days of Vaccination 4</time_frame>
        <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Stage Endpoint</title>
            <description>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Systemic Events by Severity Within 14 Days of Vaccination 4</title>
          <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment Emergent Adverse Events (AEs)</title>
        <time_frame>From Vaccination 4 up to 28 days after Vaccination 4</time_frame>
        <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Stage Endpoint</title>
            <description>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment Emergent Adverse Events (AEs)</title>
          <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment Emergent Serious Adverse Events (SAEs)</title>
        <time_frame>From Vaccination 4 up to 6 months after Vaccination 4</time_frame>
        <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Stage Endpoint</title>
            <description>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment Emergent Serious Adverse Events (SAEs)</title>
          <population>The data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs: Recorded from Vaccination 1 up to 1 month after Vaccination 3 (up to Month 2 for day regimen and Month 7 for month regimen). SAEs: Recorded from Vaccination 1 through 6 months after Vaccination 3 (Month 7 for day regimen and Month 12 for month regimen).</time_frame>
      <desc>SAEs and AEs were grouped by system organ class and preferred term. AEs included AEs collected in the e-diary (local and systemic reactions; systematic assessment) and AEs collected on the case report form at each visit (nonsystematic assessment).</desc>
      <group_list>
        <group group_id="E1">
          <title>Clostridium Difficile Vaccine(100 mcg):Day 1, 8 and 30 Regimen</title>
          <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination</description>
        </group>
        <group group_id="E2">
          <title>Clostridium Difficile Vaccine(200 mcg):Day 1, 8 and 30 Regimen</title>
          <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
        </group>
        <group group_id="E3">
          <title>Placebo: Day 1, 8 and 30 Regimen</title>
          <description>Participants received placebo saline intramuscularly on Day 1, 8 and 30 visits. Participants were followed up to 12 months after the last vaccination.</description>
        </group>
        <group group_id="E4">
          <title>Clostridium Difficile Vaccine(100 mcg):Month0, 1and 6 Regimen</title>
          <description>Participants received 100 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the third vaccination.</description>
        </group>
        <group group_id="E5">
          <title>Clostridium Difficile Vaccine(200 mcg):Month0, 1and 6 Regimen</title>
          <description>Participants received 200 mcg of Clostridium difficile vaccine intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
        </group>
        <group group_id="E6">
          <title>Placebo: Month 0, 1 and 6 Regimen</title>
          <description>Participants received placebo saline intramuscularly at Month 0 (Day 1), 1 and 6 visits. Participants were followed up to 12 months after the last vaccination.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Chemical burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="158" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="156" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="52" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Mitral valve calcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Right atrial dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Right ventricular dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Factor V deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Eustachian tube dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypogonadism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Retinoschisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Anal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Anorectal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Change of bowel habit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Diarrhoea (diarrhea)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="59" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site macule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vessel puncture site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pyrexia (fever)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site erythema (redness)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site pain (pain)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="83" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site swelling (swelling)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="81" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="69" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple allergies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Root canal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Laryngitis viral*</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Lip infection*</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pneumonia*</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Burns first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Lenticular injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vitreous injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Brain natriuretic peptide increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Ophthalmological examination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Red reflex abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Coccydynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Osteoporosis postmenopausal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Bone cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Spinal deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Arthralgia (joint pain)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Myalgia (muscle pain)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Neuroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cardiac neoplasm unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypergammaglobulinaemia benign monoclonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Abdominal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="56" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder with mixed anxiety and depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Atrophic vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Paranasal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Precancerous skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Aortic arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Aortic dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

